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DESIGN OF CONTROL RELEASE DRUG DELIVERY SYSTEM (DDS) FOR IMAGING AND
THERAPEUTIC APPLICATIONS

By Sweta H. Naik, Ph.D.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2011

Director: Dr. Everett E. Carpenter
Associate Professor of Chemistry

The main challenge in disease treatment is no more the discovery of new therapeutic
drugs, but to provide targeted delivery of therapeutic drugs to specific sites without incurring
systemic toxicity effects. An efficient way of reducing the toxicity is by encapsulating the drug
with a biodegradable matrix that can provide controlled release of the drug along with local
heating of the drug. Local heating can be obtained by incorporating magnetic iron oxide particles
that heat upon exposure to AC electromagnetic fields. The magnetic iron oxide nanoparticles are
also gaining much attention as MRI contrast agents. Thus it would be of potential benefit if a
drug delivery system is designed to encapsulate the drug as well as the magnetic iron oxide
nanoparticles within a biodegradable matrix, thereby providing a dual modal imaging and
therapeutic delivery system. The key step in the design of a dual modal drug delivery system is

xvi

the encapsulation of the magnetic iron oxide nanoparticles with polymer of choice. The magnetic
iron oxide nanoparticles were encapsulated into a robust poly (styrene-co-vinylbenzylchlorideco-divinylbenzene) (PSVBDVB) to study these synthetic variations upon encapsulation with a
polymer. The next step to the design of drug delivery system was to replace the PSVBDVB
polymer by a biocompatible and biodegradable polymer- Poly (lactide-co-glycolide) (PLGA).
The PLGA composites containing the Fe@FeOx core shell nanoparticles and the drug analog
[Ru(bpy) dye] was prepared by oil-in water emulsion solvent evaporation technique. The local
heating of the PLGA composites was also achieved by irradiating the Fe@FeOx nanoparticles
with 2.45 GHz microwave radiations. Higher Ru(bpy) dye release from the composites by
locally heating the sample with 2.45 GHz microwave pulse compared to externally heating the
composite sample was achieved.
The final step was the design of controlled release drug delivery system with dual modal
imaging and therapeutic capabilities. To obtain narrow sized PLGA composites the Fe@FeOx
nanoparticles were replaced by chloroform based ferrofluid. The ferrofluid was synthesized by
novel thermolysis technique. The release of the dye from the PLGA composites when placed in
the Rf induction coil was determined by fluorescence spectroscopy and a linear increase in the
fluorescent intensity was observed with time. Also, the controlled release of the dye from the
composites was achieved by a pulsed Rf treatment. Magnetic resonance imaging was also
performed using the PLGA composites which showed enhancement in the T 2-weighted image
contrast and thus negligible reduction in the contrast capabilities of the iron oxide particles (R 2 =
58.7 s-1mM-1).

The PLGA composites containing the drug analog and the iron oxide

nanoparticles thus constitute a controlled release drug delivery system with dual modal imaging
and therapeutic capabilities.

Chapter 1. Introduction
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1.1.Overview
Advances in the drug development and delivery have evolved in several phases,
beginning with the botanical phase of human civilization, via the synthetic chemistry era, and
now presently in the biotechnology era. Researchers are continuously developing new and
more powerful drugs, but still the drugs are administered conventionally. The conventional
route of administration of these drugs are primarily enteral or perenteral routes. Enteral route
of drug administration rely on introducing a drug to the digestive tract through the mouth or
rectum. Perenteral route of drug administration involves the injection or infusion of a drug into
the body (intravenous or intramuscular). 1,2 Many vaccines as well as the chemotherapeutic
drugs are delivered through the perenteral route of administration. 1 Oral delivery is most
attractive due to high patient convenience and compliance. In both type of administration the
resultant effect is systemic i.e. upon administration the drug molecules are distributed
throughout the body.

3,4

Several different types of cell are involved into the diseased tissues:

the diseased cells, normal cells from which the disease evolves, vascular cells, fibroblasts, and
immune cells. The systemically distributed drug metabolizes throughout the body leading to
the damage of healthy cells and tissues, resulting in general toxicity and poor acceptance of the
treatments by patients.4 For example, the treatment of cancer, HIV infections, tuberculosis,
and malaria generally involve very powerful drugs, and their use is considerably reduced due
to the occurrences of side effects. In addition, conventionally delivered drugs get diluted in the
blood and body fluids resulting in insufficient drug concentration at the diseased site. 5 Drugs
are often too quickly cleared from the blood stream due to the uptake by the reticuloendothelial
system (RES) i.e. the body’s immune system, and the kidneys. 5 This leads to a treatment
approach of higher doses, or the inconvenience of continuous infusion again resulting in
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perhaps intolerable or even more toxic levels of drugs.4 This side effects result in a dose
limiting situation where the drug administration has to be brought to a level that is just
tolerable to the patients, but may be less effective. Also the drugs may be unstable and
degrades quickly or may have a very poor solubility in aqueous solution. For instance
hydrophobic drugs get precipitated in blood plasma, and require solubilizers/stabilizers in order
to administer the drugs.6 Unfortunately, these solubilizers/stabilizers not only dilutes the
potency of the drugs but also adds up to the drug toxicity.7 Therefore, for effective treatment
it is necessary to maintain the drug concentration between the effective therapeutic level
and the maximum tolerable limit for prolonged period of time as shown in figure.8,9 The
drug release from conventional route is in a form of a burst where in the drug is released all at
a time and needs to be given on a regular basis. A controlled release drug delivery system is
desirable that can release the drug effectively in the therapeutic window over a long period of
time. This will allow for fewer drug dosage and patient compliance. This all can be achieved
by designing a controlled release drug delivery system specific for the diseased cells within the
body. The challenges presented here can be overcome by properly integrating nanotechnology
with the established knowledge of the disease characteristics.

4

Figure 1-1: Therapeutic window showing the effect of conventional burst release and
controlled release relative to the effective concentration and the maximum tolerable toxic
concentration.

1.2. Nanotechnology
Nanotechnology is an emerging field of science that can facilitate a way to overcome the
short coming to an efficient and safe drug delivery system. 10,11

Nanotechnology is an

interdisciplinary field of science which deals with the design, synthesis, characterization and
application of devices and materials in the nanoscale range. 4

Although nanomaterials are

widely considered to be an invention of modern science, they actually have a very long history.

5

Nanoparticles (NPs) were empirically used by artisans as far back as the 9th century BC in
Mesopotamia to generate a glittering effect on the surfaces of pots. Modern nanotechnology
was envisioned by the physicist and Nobel laureate Richard Feynman in his lecture “There is
plenty of room at the bottom” in 1959. Nanotechnology refers to structures roughly in the 1 to
500 nm size in at least one dimension and are developed by top-down or bottom-up
approaches.12

To put this size range in perspective, an atom, molecules, proteins, virus, cell

mitochondrium, red blood cells, and the mammalian cells are around 0.1 nm, 1 nm, 10 nm, 100
nm, 1000 nm, 10,000 nm and 100,000 nm respectively as shown in Figure 1-2. The application
of nanotechnology to life sciences has been termed as nanobiotechnology. 13-15

Figure 1-2: Representation of size of species in the nano and micron region
These nanoscale materials possess unique and unusual properties and are currently used
in multidisciplinary scientific areas that range from physics and engineering to biochemistry.
Among many unique physical and chemical properties at the nanoscale, one basic physical
property for nanomaterials is the large surface area to volume ratio. 16 For example, in bulk
materials only a relatively small percentage of atoms can be at or near the surface. When the

6

dimensions continue to shrink to the nanoscale, the percentage of bulk atoms decreases while the
surface atoms increase. This provides relatively large (functional) surface area which is able to
bind, absorb and carry other compounds such as drugs and probes.17 Also the physiochemical
properties of nanomaterials like friction and interaction with other molecules are different from
their bulk counterparts. Depending on the type of application nanomaterials can be synthesized
from different materials like iron, gold, silica, semiconductors, lipids or polymers. Also the
nanomaterials can be fabricated into different shapes such as nanospheres, nanorods, nanotubes,
nanowires. The nanomaterials due to their small size can cross biological barriers including the
blood-brain barrier, transit out of blood vessel walls or the cells by difference uptake
mechanisms thereby interacting with wide range of biological entities. These characteristics
confer nanomaterials high interaction and transport capabilities making them attractive for the
design of biosensors, imaging and/or therapeutic agents. Advances in nanobiotechnology have
heralded the advent of several innovative nanomaterials, which are set to revolutionize the field
of targeted drug delivery system.

1.3. Drug delivery system (DDS)
A drug delivery system (DDS) is defined as a system in which the bioactive agent (drug)
is integrated with a non-active agent (carrier) in such a way that the drug is released from the
carrier in a predetermined manner, at a constant rate in what is known as zero-order release, in a
cyclic manner, or in response to an external trigger such as a change in pH, ionic strength or
temperature of the medium.18-21

Ideally the carrier system, whether it is synthetic or natural,

should be able to provide a nontoxic support system that can be manufactured on an industrial
scale that can be translated into a cost-effective, clinically practical medicine.22 In addition to
controlling the rate and duration of the drug release, the DDS should be able to target the drugs
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to specific organs and tissues, as well as individual organelles within the individual cells (i.e.
tumors, bacterial cells of definite species) or respond to a biofeedback mechanism such as
glucose levels in hyperglycemia patients. The schematic of an ideal drug delivery system is
depicted in Figure 1-3.

Figure 1-3: Schematic representation of an ideal drug delivery system (DDS)
The benefits offered by controlled DDS over traditional pharmaceutical administration
include maintenance of the drug levels within desired limits, maximize the pharmaceutical drug
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activity, the need for fewer doses, and better patient compliance. 23 In addition, association of the
drug with a carrier may provide enhanced protection to the active agent from degradation in the
physiological environment, and improve the stability of the drug that is required for formulation
and administration. The field of DDS is characterized by the need of delivering the existing
drugs to specific targets in the diseased cells through specific cell reorganization
mechanism and be able to overcome the biological barriers that prevent the drug from
effectively reaching the target.

19,24-27

The application of nanobiotechnology to drug delivery

has benefited all streams of medical science with oncology being the foremost

1.4. Cancer
Cancer is a class of disease in which the cells in a part of the body begin to grow out of
control.28 Cell multiplication (proliferation) is a normal physiologic process that occurs in
almost all tissues and under many circumstances, such as response to injury, immune responses,
or to replace cells those have died or have been shed as a part of their lifecycle. Normally the
balance between proliferation and cell death is tightly regulated to ensure the integrity of organs
and tissues. But sometimes mutations in the DNA disturb the orderly process and leads to the
uncontrolled and often rapid proliferation of cells. This leads to either a benign tumor or a
malignant tumor (cancer). Benign tumors do not spread to other parts of the body or invade
other tissues, and they are rarely a threat to life. Malignant tumors can invade other organs,
spread to distant locations (metastasize) and become life threatening. Cancer is the second
leading cause of death in United States exceeded only by heart disease, with an estimate of 1.6
million new cases and 571,950 deaths in 2011.29 Symptoms and signs of cancer depend on the
type and location of the cancer, but more often the symptoms do not start until the disease has
reached an advanced stage. Most cancers are diagnosed by biopsy, and depending on the
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location of the tumor the biopsy may be simple procedure or a serious operation. So an efficient
cancer detection technique needs to develop which can diagnose the disease at an early treatable
stage. The principal treatment approach followed these days is surgery; if the tumor is accessible
and/or chemotherapy and radiation therapy that can eradicate the tumors located deep inside the
body.28

Both chemotherapy and radiation therapy suffers from their non-specific mode of

actions leading to adverse side effects.30-33 For example, the most common chemotherapeutic
agents such as paclitaxel and doxorubicin exhibit anti-cancer effects by inducing apoptotic death
of rapidly dividing cells, but they can also kill several types of normal cells that divide rapidly in
ordinary circumstances.34-37 Since the current chemotherapy is mainly based on a whole-body
treatment with the chemotherapeutic agents, it is inevitable to cause many dangerous side effects
associated with the non-selective cytotoxic effect of the medications. Thus, drug delivery in
cancer is important for optimizing the effect of drugs and reducing the toxic side effects.
Significant advances have been made in the treatment of many cancer subtypes, but the therapies
currently available, lack the patient compliance.38 The National Cancer Institute (NCI) launched
the alliance for nanotechnology in cancer for improving cancer mortality defined the path of
opportunities in the following areas:39

1. Research tools that makes it possible to rapid identification of new biological targets for
clinical developments.
2. Agents that can monitor predictive molecular changes to identify precancerous cells and
prevent them from becoming malignant.
3. Imaging agents and diagnostics that can allow clinicians to detect cancer in the earliest,
most easily treatable, pre-symptomatic stage.
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4. Multi-functional targeted systems that can deliver multiple therapeutic agents directly to
cancer cells.
5. Systems that can provide real-time assessments of therapeutic and surgical efficacy.
6. Novel methods that can manage the symptoms that reduce quality of life
The use of nanocarriers as DDS for anticancer therapeutics has great potential to
revolutionize the future of cancer therapies. In addition nanocarriers with imaging agents offer
opportunities to exploit optical imaging or magnetic resonance imaging (MRI) for cancer
imaging and guided hyperthermia therapy. 40 Inorganic nanoparticles have emerged as viable
candidate as imaging, diagnostics and sensing agents for cancer treatments. 41 The nano sized
metal and semiconductor nanoparticles possess unique electronic, optical and catalytic properties
that very significantly from the properties of their bulk counterparts. Nanoparticles based on
gold, semiconductor metals and iron oxide have been extensively studies as imaging and
diagnostic agents.40 When applied to biological systems this metallic nanoparticles have the
potential to improve the imaging techniques such as X-ray imaging, near infrared (NIR) imaging,
position emission spectroscopy (PET) and magnetic resonance imaging (MRI).

Metallic

nanoparticle probes can enhance the signal sensitivity, and spatial resolution thereby improving
the sensitivity of the imaging techniques. Of all the metallic nanoparticles, the focus has been on
iron oxide nanoparticles due to their biocompatible nature and their superparamagnetic property.
These iron oxide nanoparticles are responsive to externally applied electromagnetic radiations
and will produce heat by magnetic hysteresis and will be discussed in detail in chapter 3. In this
dissertation the focus would be on the encapsulation of the iron oxide nanoparticles with the
active agent into a polymer matrix of choice. The encapsulated nanoparticles can be inductively
heated by hyperthermia principals to obtain enhanced drug release profiles.
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1.5. Nanocarriers for cancer imaging and therapy
The use of drug delivery systems (DDS), composed of a nanocarrier and its active agent
(imaging and therapeutic agent), dramatically changes the physicochemical properties of the
drug as well as its bio-distribution. It is particularly relevant in the case of very active drugs
whose use in the clinic has been limited due to their toxicity on vital organs such as heart,
kidneys, bone marrow and it may also provide new delivery options for the existing drugs
available. The most common examples of nanocarriers are prodrugs, dendrimers, liposomes,
micelles, hydrogels, carbon nanotubes, implantable systems, and polymeric composites.42-48
Figure 1-4 shows the different types of nanocarriers used as drug delivery systems. Nanocarriers
have the potential to improve the therapeutic index of the drug by increasing the drug payload
within the carrier and achieve desired drug release, there by reducing the drug toxicity.
Nanocarriers can also improve the solubility and stability of the drug, allowing a higher drug
payload.
Prodrugs are pharmacological substances that are administered in the inactive form and
are metabolized in vivo into the active form. 49,50 Prodrugs are used when the drugs have
unattractive physiochemical properties. They are generated through the chemical conjugation of
an active agent with a carrier molecule, which could be a polymer or lipid. Dendrimers are
highly branched macromolecules of very small size, and mono-distributed molecular weight that
can be used to deliver high payloads of drugs through conjugation of the active agent with the
numerous surface or interior functional groups. 51-53 The term originates from ‘dendron’ meaning
a tree in Greek.

Dendrimers are generally prepared using either a divergent method or a

convergent one. Both prodrugs and dendrimers have the disadvantage of chemically modifying

12

the active agent, possibly affecting its in vivo activity.53-56 Liposomes are artificially prepared
vesicles consisting of vesicles formed by phospholipids bilayers, and which deliver the drug into
cells by fusing with cellular membranes. 48,57,58

Liposomes can be prepared by disrupting

biological membranes, for example by sonication. Micelles consist of self-assembled vesicles
formed by lipids or other amphiphilic molecules (including polymers), which can be used for
encapsulation and isolation of hydrophobic molecules from the surrounding hydrophilic
physiological environment.47,59,60 A typical micelle in aqueous solution forms an aggregate with
the hydrophilic "head" regions in contact with surrounding solvent, and the hydrophobic "tail"
regions in the micelle center.

Liposomes and micelles offer advantages such as prolonged

circulation time, altered pharmacokinetics, and the ability to encapsulate highly hydrophobic
drugs, but do not usually provide controlled release over time. 61-64 Hydrogels are materials
capable of uptaking significant amounts of water and swelling in result to changes in the
surrounding environment, resulting in increased pore sizes that allow controlled release of its
contents.65,66 Drug delivery systems based on hydrogels have been shown to result in low drug
burst effects, but do not usually provide long term drug release. 62

Carbon nanotubes are

allotropes of carbon (graphene) with a cylindrical shape. 67,68 Carbon nanotubes have many
structures, differing in length, thickness, and in the type of helicity and number of layers.
Although they are formed from essentially the same graphite sheet, their electrical characteristics
differ depending on these variations. Carbon nanotubes in higher concentrations can interact
with the body fluids and alter the function of the immune systems. 69-71 Implantable systems can
provide long term drug release, but require invasive interventions for implantation and removal,
thus resulting in lower patient acceptability. 72,73 Polymeric composites encapsulate drugs in
either a reservoir or matrix arrangement, in which the drug is either localized to the center of the
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particle and surrounded by a polymer layer, or dispersed throughout a polymeric matrix,
respectively.74,75 Polymeric nanocomposites have shown advantages over nanocarriers in term
of stability, storage, desired drug release kinetics, toxicity and in-vivo activity.

Figure 1-4: Types of nanocarriers
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1.6. Polymeric composites
Polymeric composites are attractive for medical purpose due to their relatively large
functional surface which can carry, bind or absorb other chemical materials like drugs, proteins,
genes, and imaging probes.43,44

Depending on the conformation, and on the material used to

fabricate the polymeric composites various drug release kinetic profiles including constant (zeroorder) release can be obtained by the combined effects of drug diffusion and polymer
degradation.

Polymeric composites can be classified into nano-composites and micro-

composites based on their sizes. The micro-composites range in diameter from 1 to 250μm,
while the nanocomposite ranges between 10 to 1000nm.

Polymeric composites can be

synthesized from number of different natural and synthetic polymers. 76 Some of the naturally
occurring polymers used are dextran, cellulose, chitosan. 76

Synthetic polymers used for

composite synthesis are poly (methyl methacrylate) (PMMA), poly (styrene-co-vinylbenzyl
chloride-co- divinyl benzene) (PSVBDVB), polylactic acid (PLA), poly glycolic acid (PGA),
poly (lactic-co-glycolic acid) (PLGA)76-78. Non-biodegradable synthetic polymers like PMMA,
PSVBDVB are used for synthesizing composites but are not suitable for in-vivo applications as
they need to be removed surgically.79 The polyesters like PLA, PGA, and PLGA are approved
by Food and drug administration (FDA) for human applications due to their biodegradability,
biocompatibility, and lower toxicity and will be discussed in detail in chapter 5.28,78

Polymeric

composites, in addition, because of their small size, are able to circulate through capillaries,
preferentially escape into tumor tissue because of the enhanced permeability and retention effect
(EPR), and may be taken up by cells for intracellular drug delivery, and will be discussed in the
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“targeted drug delivery” section. It is these properties of nanoparticles that have been exploited
for the development of the targeted delivery system in this project.

1.7. Preparation of Polymeric nanoparticles
Polymeric composites can be prepared either by directly from the monomers by
conventional polymerization processes or can be fabricated from the pre-synthesized polymer.
The conventional polymerization approach uses the monomer as the starting point. Precipitation
polymerizations and emulsion polymerization are some of the examples of conventional
polymerization approach.76,79,80 The preparation of the polymeric composites from the presynthesized polymers can be achieved by techniques such as emulsification solvent evaporation
technique, salting out, spray drying, and nanoprecipitation to name some.78,81-84 The selected
method determines the characteristics of nanocomposites, including the size, as it the most
important property because it is strongly related to the administration mode. 85 Another property
influenced by the preparation process is the ability to interact with active principles contained in
the drugs formulation. As a consequence, a deep knowledge of the experimental parameters like
the solvents, temperature, kind of stabilizer, and stirring rate involved in each method are crucial
and can bring on the characteristics change in the resulting composites.
1.7.1. Precipitation polymerization
Precipitation polymerization is a type of conventional approach for the preparation of the
nanocomposites.

Precipitation polymerization is a heterogeneous polymerization process that

starts with a homogeneous system in the continuous phase, where the monomers and initiator are
completely soluble, but upon initiation the formed polymer is insoluble and thus precipitates
outs.79 86 After precipitation of the polymer the polymerization continues with the adsorption of
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the monomer and initiator on the surface of the formed polymeric particle leading to the growth
of the particle. Encapsulation of the active agent (therapeutic agent/ imaging probe) can be
achieved by adding it along with the monomer initiator assembles. In this technique it is difficult
to obtain control over the size and morphology of the formed nanocomposites.
1.7.2. Emulsion polymerization
Emulsion polymerization is also a type of conventional approach used for the preparation
of composites.

Emulsion polymerization is a type of radical polymerization where in the

polymerization process starts within the emulsion formed by the monomer, initiator and water. 8688

Encapsulation of the active agent can be achieved by adding it along with the monomer

initiator assembles. Polymerization is initiated by diffusion of a free-radical into the emulsion.
The monomers continuously diffuse from the aqueous phase into the emulsion droplets. Due to
the small dimensions of the droplets, diffusion of another free-radical into the droplets leads to
quick termination as a result of coupling of the free-radicals. Thus, the polymerization occurs via
a single growing chain. Hence, the molecular weight of the polymer bead can become very high
before termination.87,88
1.7.3. Emulsification solvent evaporation technique
Emulsification solvent evaporation is the most promising technique employed for the
preparation of polymeric nanocomposites. The method is based on the emulsification of an
organic solution of the polymer in an aqueous phase followed by the evaporation of the organic
solvent.89-91 The polymer is dissolved in a suitable solvent such as ethyl acetate, chloroform,
methylene chloride. The organic phase or aqueous phase is poured into the continuous phase
(aqueous or organic phase) to form the emulsion, which is stabilized by dissolving a surfactant
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into the continuous phase.

Emulsification is carried out under high-shear stress to reduce the

size of the emulsion droplet which is directly related with the final size of the nanocomposites.
The process of emulsification is followed by evaporation of the organic solvent under vacuum,
which leads to polymer precipitation and nanoparticle formation. This method has two
alternatives depending on the nature of the active agent to be entrapped within the
nanocomposites: normal emulsions-oil-in-water (o/w) and double emulsions-water-in-oil-inwater (w/o/w) techniques.90
1.7.3.1. Oil-in-water emulsion technique:
The technique is based on the emulsification of an organic solution containing the
polymer and the active component in an aqueous phase, followed by the evaporation of the
organic solvent. Different surfactants such as poly vinyl alcohol (PVA), sodium dodecyl sulfate
(SDS) or Pluronic F68 can be dissolved in the aqueous phase to stabilize the emulsion formed.
The size reduction of the emulsion droplet is done by sonication or homogenization to achieve
nanosized composites. The evaporation step is required to eliminate the organic solvent present
in the organic phase and leads to the precipitation of the polymer as nanocomposites with a
diameter in the nanoscale range.

This technique is suitable for considerable number of

hydrophobic agents that are soluble in variety of water immiscible solvents and, are poorly
soluble in water.

Figure 1-5 represents the schematic representation of the oil-in-water

emulsification technique. Important parameters to be considered for the o/w emulsion are:
molecular mass and the concentration of the polymer used, co-polymer ratio and end groups
employed to functionalized the polymer, type and concentration of the surfactant used, phase
ratio, solvent nature, evaporation rate, drug entrapment, additives used, and the shear stress
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applied.92 o/w emulsion technique has been employed to prepare the PLGA nanocomposites in
this project and will be discussed in depth in the following chapters.

Figure 1-5: Schematic representation nanocomposite preparation by oil-in-water emulsion
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1.7.3.2.Double emulsion (w/o/w) technique
Double emulsion technique is most often used to encapsulate hydrophilic compounds.
The initial step of the double emulsion technique is the formation of water-in-oil (w/o) emulsion.
The hydrophilic agent is dissolved in small volume of aqueous phase and this is emulsified in an
organic phase containing the polymer. The w/o emulsion formed is further dispersed into larger
volume of aqueous phase to form the double w/o/w emulsion. 93,94 The w/o/w emulsion formed is
sonicated or homogenized for droplet size reduction. The size reduction carried out under strong
shear stress has to be carried out carefully to minimize the hydrophilic drug diffusion to the
external aqueous phase. The final step is the evaporation of the organic solvent which is carried
out under vacuum to avoid polymer and component damage. The important parameters that
need to be considered are: type and concentration of the polymer used, surfactant nature,
polymer/surfactant ratio, solvents used, shear stress applied, evaporation and most important the
ratio of the first/second phase.
The main drawback of the double emulsion technique is the large particle size and low
entrapment efficiency of the drug. 93,95 The mechanism responsible for the poor entrapment
efficiency is the diffusion of the hydrophilic active agent through the organic phase. Also, the
application of intense shear stress may cause degradation of the drug component. 93
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1.7.4.Salting out technique

Figure 1-6: Schematic representation of nanocomposites preparation by salting out
technique
In the salting out technique the polymer of choice and the active component are dissolved
in water miscible solvents such as acetone, ethyl acetate or tetrahydrofuran. This organic
solution is emulsified under vigorous mechanical stirring in an aqueous phase containing high
concentration of the salting out agent and the colloidal stabilizer. This o/w emulsion is diluted
with sufficient volume of water, under mild stirring. This reduces the ionic strength of the
solution leading to the diffusion of the water miscible solvent into the aqueous phase, inducing
the nanocomposites formation. The final step is the purification by cross-flow filtration to
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remove the salting out agent.96,97 Common salting out agents used are electrolytes like sodium
chloride, magnesium chloride or magnesium acetate and non-electrolytes like sucrose.96 Figure
1-6 represents the schematic representation of the salting out technique for nanocomposite
preparation. Important parameters to be considered are: molecular mass and concentration of
the polymer used, mechanical stirring rate and time, nature of surfactant use, nature of the
salting out agent used, type of water miscible solvent.
The main drawback of the salting out technique is the requirement of and added
purification step for the removal of the salting out agent used which is in high concentrations.
Also the salts used are at times not compatible with the active agents.

Furthermore, this

technique is suitable for the encapsulation of the lipophilic drugs only. 98

1.7.5.Nanoprecipitation technique
In the nanoprecipitation technique the polymer and the active agent are dissolved in a
water miscible organic solvent such as acetone or ethyl acetate. The organic phase is then
slowly poured in a controlled manner into an aqueous phase containing the surfactant such as
PVA or poloxamer 188 under mild stirring. Nanocomposites are instantaneously formed due to
immediate reduction of the interfacial tension with rapid diffusion of the water miscible into the
aqueous phase.

The organic solvent is removed by evaporation and the nanocomposite

suspension is concentrated under reduced pressure, centrifuged and freeze dried to obtain
nanocomposites.99,100

Important parameters to be considered are:

polymer concentration,

nature of the surfactant used, polymer/surfactant ratio, nature of the solvent used, and the phase
addition.100
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Nanoprecipitation technique is only suitable for hydrophilic agents because of their poor
interaction with the polymer which leads to a considerable leakage of the drug into the aqueous
phase during preparation. Also, the active agent to be encapsulated needs to be highly soluble in
the polar solvent and slightly soluble in water. 101
1.7.6. Spray drying

Figure 1-7: Schematic representation of nanocomposite preparation by the spray drying
technique
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Spray drying technique enables the transformation of feed from a fluid state into dried
particulate form by spraying the feed into a hot drying medium. It is a continuous particle
processing drying operation as shown in Figure 1-7. The feed can be a solution, suspension,
dispersion or emulsion. The dried product can be in the form of powders, granules or
agglomerates depending upon the physical and chemical properties of the feed, the dryer design
and final powder properties desired. Large batch sizes are typically required as compared to
emulsion techniques; therefore spray drying technique is often problematic.

1.8. Targeted drug delivery of the polymeric nanocomposites to the tumor
sites
There are several targeting strategies that can be used to concentrate nanocomposites
selectively at tumor sites by exploiting differences between malignant and normal cells.

The

two main drug targeting strategies employed are- passive targeting and active targeting.18
1.8.1. Passive targeting:
Passive targeting takes advantage of the anatomical difference between the normal and
tumor tissues to deliver the drug at the tumor site. As the tumor grows (~2mm in diameter) the
normal tissues are displaced. The growing tumor activates the angiogenic process, to generate
new blood vessels towards the tumor to supply oxygen and nutrients. The newly formed tumor
blood vessels vasculature is very different from normal blood vessels, as they are dilated,
irregular in shape and leaky or defective due to poorly organized endothelial cells. 21 The
disorganized pathology of angiogenic tumor vasculature with a discontinuous endothelium leads
to hyperpermeability to circulate the nanocomposites and lack of effective tumor lymphatic
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drainage leads to subsequent accumulation of the nanocomposites. This increased permeability
of the tumor vasculature is the key feature in passive targeting of the nanocomposites. This is
popularly known as enhanced permeability and retention effect (EPR) which results in the
accumulation of macromolecular drugs and polymeric nanocomposites at the tumor site and
thus increasing the drug concentration. 3,102 By taking the advantage of the EPR effect the DDS
can progressively but selectively build up within the tumor cells and deliver drugs with higher
drug concentrations compared to the normal cells. Figure 1-8 illustrates the enhanced delivery
of the drug through the ERP effect with less normal cell targeting.
Localized delivery is another approach in which the drug loaded nanocomposites can be
directly delivered to the target site thus minimizing the circulation of the drug and lowering
toxicity.25 This method is only suitable for the tumors that are easily accessible.

25

Figure 1-8: Illustration of the passive targeting approach with enhanced delivery of the
drug to the tumor site due to the ERP effect
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1.8.2. Active targeting:
Active targeting strategy exploits the specific binding affinities of targeting
ligands that are bound to the nanocomposite system used to bind to the target site receptor
functionalities, thereby allowing preferential accumulation of the drug within the tissue or
cells.3,18,102 This strategy also takes the advantage of the EPR effect for the accumulation of the
nanocomposites into the interstitial fluid of the tumor and is illustrated in Figure 1-9. The main
parameter to be kept in mind is the proper selection of the targeting agent, which should be
available in abundance, should have high affinity and selectivity of binding to the cell surface
and should be apt to chemical changes on conjugation. The identity and characteristics of the
targeting agent are also important for longer circulation time, cellular uptake, affinity, and
removal of the nanocomposite. Therefore, a specific binding capacity of the targeting agent to
tumors is essential in the success of the drug delivery system. An increased site specificity and
internalization can improve the efficacy of treatment and decrease the possibility of the serious
side effects. Ligands such as antibodies, saccharides, aptamers, hormones, lectins and low
molecular compounds binds to their specific receptor on the cellular surface and trigger the
internalization process of the drug by means of receptor-mediated endocytosis (REM). Surface
receptors like folate receptor (FR), the transferrin receptor (TfR) and the epidermal growth factor
reseptor (EGRF) have been highly investigated for site specific targeting. 103-105
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Figure 1-9: Active targeting strategy for the delivery of drugs through ligand-receptor
interaction.

1.9. Folate receptor
Folic acid (FA) also known as folate or vitamin B9 is a low molecular weight (MW-441)
water soluble vitamin required by all living cells for nucleotide biosynthesis and for normal
metabolic maintenance of 1-carbon pathways.

Cellular uptake of folates are facilitated by

either a low affinity reduced folate carrier which is present in virtually all cells of the body, or a
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high affinity folate receptor (FR) which exhibits highly limited distribution within the body
cells. The folate receptor is a 38 kDa glycosyl-phosphatidylinositol-anchored glycoprotein that
has the affinity for both folic acid and folate linked cargos. 106 Two membranous forms of FRalpha (α) and beta (β) have been identified. Both α and β forms have high FA binding affinity,
however they display some difference with respect to their affinity for antifolates. 107,108 The
reduced folate carrier is selective in facilitating transport of reduced forms of folic acid only
while the FR has the ability to transport both folic acid and folate-linked cargos. Once the
folate linked cargos are conjugated to the cell surface FR they are internalized into the cells
through a process called receptor-mediated endocytosis.

Figure 1-10: Structure of Folic acid
It has been found that FR is up-regulated in more than 90% of non-mucinous ovarian
carcinomas. It is also found at high to moderate levels in kidney, brain, lung, and breast
carcinomas while it occurs at very low levels in most normal tissues.

The FR density also

appears to increase as the stage of the cancer increases. 18,106 In addition, folic acid is required
for essential cell function, therefore the cargo attached to the ligand are retained within an
endocytic vesicle. While, the cargos attached to antibodies, hormones, and other related ligands
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are normally internalized to clear the ligand from the receptor. Exploiting the above-mentioned
facts, it can be hypothesized that folic acid conjugation to polymeric nanocomposites will
improve drug selectivity and decrease negative side effects.

Folic acid has emerged as an

attractive ligand for drug targeting due to its low molecular size, which allows for good tissue
penetration. The structure of folic acid (FA) is shown in Figure 1-10. Also folic acid can be
easily attached to the polymeric composites through carbodiimide chemistry and will be
discussed in detail in chapter 6.

1.10. Summary of Objectives
The overall goal of this dissertation work is to develop and design a novel controlled
release drug delivery system (DDS) with imaging and therapeutic capabilities.

The polymeric

coating used helps reduce the toxicity of the active agent. Some of the main objectives of this
dissertation work are:
1. Study the synthetic variation upon encapsulation of the magnetic iron/iron oxide
nanoparticles by synthetic polymer. Also, study the dilution effect of the saturation
magnetization of the iron/iron oxide nanoparticles due to the polymer coating.
2. Develop nano sized mono-dispersed biodegradable poly (lactic-co-glycolic acid) (PLGA)
composites containing the iron/iron oxide nanoparticles as dual modal imaging and
therapeutic drug delivery carrier.
3. Study the release of the drug analog from the magnetic polymeric composites upon
heating due to magnetic hyperthermia phenomenon with electromagnetic radiations.

Chapter 2. Characterization techniques
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2.1. Introduction
The characterization of the synthesized nanomaterials is a very important stage for the
advancement of quality scientific research.

From the development of the nanomaterial’s

synthesis technique to the quality control testing of the already established techniques,
characterization of the nanomaterial is essential. The characterization of the material aids in the
precise identification of phases, size, morphology, material impurities, and surface chemistry
effects of the material. Characterization of the nanomaterials synthesized plays an important role
in the scientific research development; hence this chapter will be focused on some of the
principal characterization techniques used in this research work.
Characterization technique

Application

X-ray Diffraction (XRD)

Phase Composition, crystal shape and
crystallite size

Scanning electron microscopy (SEM) and
Transmission electron microscopy (TEM)

Nanomaterial size and morphology

Thermogravimetric analysis (TGA)

Mass change in materials associated with
dehydration, decomposition, and oxidation

Vibrating sample magnetometry (VSM)

Magnetic property and corecivity
measurements

Fluorescence spectroscopy

Track (bio-) chemical reactions

Fourier transform infrared spectroscopy (FTIR)

Functional group analysis

Ultraviolet-visible spectroscopy (UV-vis)

Characterization and quantitative
determination of analytes

Table 2-1 Principal characterization techniques used
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2.2. X-ray Diffraction (XRD)
X-ray powder diffraction (XRD) is an instrumental technique that is used to identify
crystalline materials and it is a fast and a reliable tool for material identification. X-rays are
electromagnetic radiation with energies in the range of 100 eV - 100 keV. For diffraction
applications, only short wavelength x-rays (hard x-rays) in the range of a few angstroms to
0.1˚A are used. As the wavelength of x-rays is equivalent to the size of atoms, they are ideally
suited for probing the structural arrangement of atoms and molecules in a wide range of
materials. The energetic x-rays can penetrate deep into the materials and provide information
about the bulk structure. X-rays primarily interact with electrons in the atoms. When x-ray
photons collide with sample, a portion of the beam will be scattered in all directions from the
material and constructively interfere in distinct directions based upon the symmetry of the
repeating crystal structure associated with the sample material. The angle where the peaks in
the x-ray diffraction spectrum occur is given by Bragg's law (Eq.2.1):

nλ=2d(hkl)sinθ

2.1

Where λ is the wavelength of the x-ray beam, d(hkl) is the spacing between the (hkl)
crystallographic plane contributing to the diffraction peak, θ is the angle of incident x-ray, and n
is an integer for the order of reflection. This phenomenon creates diffraction patterns as you
scan the incident angles, which are typically reported and graphed as 2θ. This diffraction
patterns have been calculated and experimentally tabulated into data bases for easier matching
and sample crystal structure determination. Figure 2-1 represents the diffraction of the x-rays by
plane of atoms. It is important to note that the d-spacing provides a unique fingerprint of the
sample materials under investigation.
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Figure 2-1: Diffraction of the x-rays by plane of atoms

The primary application of XRD is to investigate the structural nature of the material, for
example, the size and crystallinity of the sample material. A material’s structural nature can be
crystalline or amorphous. In crystalline materials a higher degree of constructive interference
will occur, thereby producing sharp constructive diffraction lines in the XRD pattern. While in
amorphous materials there are edges, mild distortions, and finite crystalline planes that will cause
a broadening affect in the diffraction pattern. There are many factors that may also contribute to
the broadening of diffraction lines, for example, instrumental broadening, micro-strain (lattice
strain), powder inhomogeneity, and temperature. Broadening in the diffraction pattern can also
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occur with a reduction in particle or crystallite size. Peak width due to crystallite size varies
inversely with crystallite size. So as the crystallite size gets smaller, the peaks get broader. Paul
Scherrer, first observed that small crystallite size could give rise to peak broadening. He derived
a well-known equation for relating the crystallite size to the peak width, which is called the
Scherrer formula (Eq.2.2)

(

)

2.2

For this equation, λ is wavelength of the incident x-ray and θ is the angle of the incident
x-ray obtained from the center of the diffraction peak, B refers to the peak width, typically
referred to as the full width at half maximum (FWHM) of the diffraction peak, L the crystallite
size and K is the Scherrer constant, typically 0.94 for spherical particles with cubic symmetry.
The Scherrer equation is limited to nano-scale particles and is not applicable to grains larger than
about 0.1 μm. A small impurity in a sample is enough to overwhelm the diffraction pattern and
gives a size value much larger than would be representative of the majority of the sample in
question. This is a major reason that other particle size determining methods such as TEM, SEM
are required for nanomaterials research. Another reason for utilizing other size determining
methods is that only crystalline materials are apparent in the XRD diffraction pattern. This
means that amorphous regions, say on the surface of nanoparticles would not be included in the
sizes determined by XRD. Also band broadening becomes a major factor in nanoparticles
research. Even for crystalline materials, once below 5-10 nm the diffraction pattern peaks appear
more as broad humps than spikes. As the peaks broaden it becomes more difficult to separate the
background, sample, and impurities.
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Figure 2-2: Schematic representation of the X-ray diffractometer
Figure 2-2 shows the schematic of the θ: θ x-ray diffractometers. In the θ: θ x-ray
diffractometers the sample is stationary in the horizontal position, and the X-ray tube rotates at a
rate -θ°/min and the detector rotates at a rate of θ °/min. The other type of x-ray diffractometer
is θ: 2θ in which the X-ray tube is stationary, the sample moves by the angle θ and the detector
simultaneously moves by the angle 2θ. The drawback of θ: 2θ x-ray diffractometer is that at
high values of θ small or loosely packed samples may have a tendency to fall off the sample
holder. In the commercial x-ray diffractometer the X-rays are generated from an X-ray tube
under vacuum when the filament within the tube is heated by the application of a current. The
numbers of electrons emitted from the filament are directly related to the amount (voltage) of the

36

applied current. The high voltage accelerates the electrons towards a target, typically made of
copper or molybdenum; the wavelength of the X-ray is dependent on the type of the target. Next,
these x-rays are directed towards the finely ground sample and finally, the detector detects the
signal which will be processed either electronically or by microprocessor to a count rate.
For the purposes of this work, powder X-ray diffraction (XRD) was taken on a
Panalytical X’pert pro diffractometer. A copper anode was used as the source of x-rays with a
current of 45 mA at an accelerating voltage of 40 kV. As described previously, the copper source
emits x-rays with Kα1 and Kα2 wavelengths of 1.540 ˚A and 1.544 ˚A respectively. The dried
powder samples were gently ground using a mortar and pestle and then pressed onto a zero
background, low volume silicon sample holder. The sample holder was then placed in the
instrument for XRD analysis. Upon completion of the run, the data were analyzed in the
Highscore plus program, which has a built-in diffraction library to compare the samples
diffraction pattern to the diffraction patterns in the JCPDS-ICDD database.

XRD was used for

phase identification, identifying the purity of samples, and determining the crystallinity of
products.

2.3. Scanning electron microscopy (SEM)
Scanning electron microscope (SEM) uses a focused beam of high-energy electrons to
generate a variety of signals at the surface of solid sample. The signals derived from electronsample interactions reveals information about the sample including external morphology
(texture), chemical composition, and crystalline structure and orientation of materials making up
the sample. The combination of higher magnification, larger depth of focus, greater resolution,
and ease of sample observation makes the SEM one of the most heavily used instruments in
research areas today.
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Figure 2-3: Schematic of the main components of SEM
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Figure 2-3 shows a schematic of the main components of the SEM. The electron beam,
which typically has an energy ranging from 0.5 keV to 40 keV, is focused by one or two
magnetic lenses to a spot about 0.4 nm to 5 nm in diameter. The beam passes through pairs of
scanning coils or pairs of deflector plates in the electron column, which deflect the beam in the x
and y axes so that it scans in a raster fashion over a rectangular area of the sample surface. The
electron beam interacts with the sample and emits out a variety of signals. These signals include
secondary electrons (SE) which are emitted from the surface as they are knocked out of the
valence orbitals of the surface atoms, backscattered electrons (BSE) which are scattered off the
surface, and photons (characteristic X-rays that are used for elemental analysis and continuum Xrays) as depicted in Figure 2-4
The secondary electrons are used to create an image of the surface, which has a 3D
quality as the angle of the secondary electron projection depends on the angle of the incoming
beam. Thus steep surfaces and edges tend to be brighter than flat surfaces, which results in
images with a well-defined 3D appearance. A backscattered electron profile is also collected as
the number of backscattered electrons increases with atomic number, so atoms of a higher atomic
number appear brighter in the image. The photons are produced by inelastic collisions of the
incident electrons with electrons in discrete orbitals (shells) of atoms in the sample. As the
excited electrons return to lower energy states, they yield X-rays that are of a fixed wavelength.
Thus, characteristic X-rays are produced for each element in sample material that is "excited" by
the electron beam. The SEM is routinely used to generate high-resolution images of shapes of
objects and to show spatial variations in chemical compositions. Precise measurement of very
small features and objects down to 50 nm in size can be accomplished using the SEM. Also the
SEM analysis is considered to be "non-destructive"; that is, x-rays generated by electron
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interactions do not lead to volume loss of the sample, so it is possible to analyze the same
materials repeatedly.

Figure 2-4: Origin and information depth of secondary electrons (SE), backscattered
electrons (BSE), and x-rays in the diffusion cloud of electron beam into the sample
In this research work the size, size distribution, and morphology of the samples were
determined using Hitachi SU-70 field emission scanning electron microscope (SEM) equipped
with digital image acquisition, EDX, WDX, EBSP, STEM, BSE, CL detectors. The morphology
of the nanomaterial sample is represented in the SEM image by dark and grey areas. The
contrast is due to the interaction of the electron beam with the sample. The SEM samples are
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prepared by lightly sprinkling the powdered sample on a conductive carbon tape mounted on the
sample holder. The sample is then lightly pressed to seat and then sprayed with canned air to
remove any loose sample from top. The sample was then sputtered with gold to make it
conductive and reduce charging. Charging is a buildup of excess of electrons (charge) on the
surface of the non-conductive sample, which causes an undesired electron beam deflecting
leading to an increase in the brightness of the image. The sample holder is then placed in the
sample compartment of the microscope and the images are obtained as described above.
SEM can provide precise resolution around ±50 nm and has ±200,000 X resolution
power, but for nanoparticle research higher resolution up to few angstroms is desirable. For this
purpose transmission electron microscopy (TEM) is utilized which has a resolution around ± 0.2
nm. Both TEM and SEM utilize electron beams to detect the size and morphology of sample
materials. In a SEM image is produce from electrons detected after scattering off the surface of
the sample where as in a TEM image is produced by electrons passing through the sample placed
on a grid. The electron density of the solid nanomaterial sample scatters some of the electrons,
with the remaining electron beam passing by to produce a silhouette of the material on a screen
for imaging. The TEM image provides information about the size, shape, size distribution, and
uniformity. Also the core-shell nature of the nanomaterial sample can also be determined by the
difference in the electron density. High resolution TEM can see lattice fringes and can be used
for electron diffraction which will give insight into the crystal structure similar to XRD. In this
work the TEM was performed on Carl Zeiss Libra 120 Plus Field Emission Transmission
Electron Microscope (TEM) to evaluate the size and morphology of the synthesized
nanoparticles.
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2.4. Thermogravimetric analysis (TGA)
Thermogravimetric analysis (TGA) is an instrumental technique where in the mass of the
sample in a controlled atmosphere is recorded continuously as a function of temperature or time
as the temperature of the sample is increased linearly with time.

The thermogravimetry

instrument consists of a sensitive analytical micro balance, furnace, purge gas system for
providing an inert atmosphere and a computer and processor for instrument control and data
recording. Figure 2-5 represents the schematic representation of the components of a thermal
gravimetric balance.
TGA provides quantitative measurement of mass change in materials associated with
transition and thermal degradation. TGA records change in mass from dehydration,
decomposition, and oxidation of a sample with time and temperature. The most important
application of thermogravimetric technique is found in the study of polymers. Thermograms
provide information about the decomposition mechanism for various polymers.
uniformity in the polymer can be known.

Also the

A tactic polymer would have fewer number of

decomposition events as compared to an atactic polymer.

The

application

of

TGA

in

nanomaterial research is to determine the amount of organic ligands/impurities that are adsorbed
onto a nanoparticle surface formed during the synthesis procedure. This percentage of organics
associated with the total mass of the nanoparticle is important information for magnetization
mass correction as it is dependent on the mass of the magnetic material and not the total mass of
the system.

It also provides information about the mass percentage of the organics in the

sample. This information can give indication of how well a surface is coated with a functional
ligand, and in some way give insight to the surface area to volume ratio of the sample.
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Figure 2-5: Block diagram of the Thermogravimetric analyzer

TGA also offers an easier way of annealing samples where in the sample size is critical.
This use may not be as common, but has the advantage of working with smaller sample size than
a traditional heating furnace, such as a tube furnace. It also allows for the monitoring of mass
loss of a sample under different gaseous atmosphere.

In this work the thermogravimetric

analysis was performed on a TA instruments Q5000 thermogravimetrtic analyzer. The sample is
positioned on a platinum pan that is supported on an analytical balance which located outside the
furnace chamber. After the balanced is zeroed, the sample is heated and the weight signal is
stored as a function of temperature and time.
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2.5. Vibrating sample magnetometry (VSM)
The vibrating sample magnetometer is an analytical instrument employed for determining
magnetic properties of a large variety of materials: diamagnetic, paramagnetic, ferromagnetic,
ferromagnetic and antiferromagnetic. This experimental technique was invented in 1956 by
Simon Foner, a scientist of the MIT. A vibrating sample magnetometer (VSM) operates on
Faraday's Law of Induction, which states that a change in magnetic field will produce an electric
field. This electric field can be measured and provides information about the changing magnetic
field. As shown in Figure 2-6 VSM operates by first placing the sample in a constant magnetic
field. If the sample is magnetic, this constant magnetic field will magnetize the sample by
aligning the magnetic domains or magnetic spins with the applied field. If the sample vibrates in
a sinusoidal motion, an electrical signal can be induced between two coils (pick-up coils)
according to the Faraday’s law. This electric signal has the same frequency of vibration and the
amplitude is proportional to the magnetization of the sample. The produced current will be
amplified and then using a computer interface that contains a specific software system,
information about the magnetization of the sample and its dependence on the magnetic field
could be obtained.
The ability to perform measurements at various temperatures is available for the VSM
but the resolution and sensitivity is not comparable to that of the SQUID, and thus most of the
VSM are set up to measure at room. The main advantage that the VSM offers to material
research is that the measurements can be done much more quickly than using a SQUID, and do
not require liquid He.

A Lakeshore model 7300 room temperature vibrating sample

magnetometer was used determine the magnetic properties of materials in this research work.
The measuring field was oriented either parallel or perpendicular to the plane of the sample
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depending on the sample shape i.e. for example pellets were oriented parallel, while powders
were oriented perpendicular to the magnetic field.

Figure 2-6: Schematic showing the main components of vibrating sample magnetometer
(VSM)
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2.6.Fluorescence spectroscopy
Fluorescence spectroscopy is a type of electromagnetic spectroscopy where the molecules
of the sample are excited by irradiation at a definite wavelength of light (usually ultraviolet) and
emit radiation of lower energy (higher wavelength).
information for both qualitative and quantitative analysis.

The emission spectrum provides
When light of an appropriate

wavelength is absorbed by a molecule (i.e., excitation), the electronic state of the molecule
changes from the ground state to one of many vibrational levels in one of the excited electronic
states. The excited electronic state is usually the first excited singlet state, S1 (Figure 2-7).
Collisions with other molecules cause the excited molecule to lose vibrational energy until it
reaches the lowest vibrational state of the excited electronic state. The molecule then drops down
to one of the various vibrational levels of the ground electronic state again, emitting a photon in
the process. As molecules may drop down into any of several vibrational levels in the ground
state, the emitted photons will have different energies, and thus frequencies.

Fluorescence is

one of these processes that correspond to the relaxation of the molecule from the singlet excited
state to the singlet ground state with emission of light. The wavelength and thus the energy of
the emitted light are dependent on the energy gap between the ground state and the excited state.
The fluorescence quantum yield (Φ) gives the efficiency of the fluorescence process. It is defined
as the ratio of the number of photons emitted to the number of photons absorbed (Eq. 2.3).

∑

2.3

Where kf is the rate of spontaneous emission of radiation and ∑ iki is the sum of all rates of
excited state decay. Other rates of excited state decay are caused by mechanisms other than
photon emission and are therefore called "non-radiative rates", which can include: dynamic
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collisional quenching, near-field dipole-dipole interaction internal conversion and intersystem
crossing as shown in Figure 2-7.

Figure 2-7: Electronic transition energy level diagram
In this research work fluorescent dyes Tris-(2,2'bipyridyl)dichlororuthenium (II),
Rhodamine B were used as the drug analog. The release of these dyes from the polymeric
composites was determined using the fluorescence spectroscopy. Fluorescence spectroscopy is
recognized as one of the most sensitive technique, and it is possible to measure the concentration
of the fluorescent substance at nano gram levels.

This work was carried out on Cary Eclipse

Fluorescence Spectrophotometer equipped with a xenon lamp.

Figure 2-8 represents the
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schematic representation of the fluorescence spectroscopy. The light from the xenon source that
is excited passes through the monochromator and lands on the sample. The sample absorbs a
portion of the incident light and the fluorescent molecules in the sample emit the light. A
detector is attached at a viewing angle (usually around 90 degrees), which prevents incident light
from contaminating the detected fluorescent light.

Figure 2-8: Block diagram of a fluorescence spectroscopy

2.7.Fourier transform infrared spectroscopy (FTIR)
Infrared spectroscopic technique utilizes lower energy infrared (IR) radiation (10000 –
100 cm-1) to induce vibrational and rotational excitation of atoms and groups of atoms within a
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molecule. When the frequency of the incident light equals to resonant frequencies of the internal
molecular vibrations in a material, absorption occurs causing the molecule to vibrate in a higher
energy level. Absorption occurs when the incoming IR radiation that is interacting with a
molecule has sufficient energy to raise the vibrational energy level of the molecular system to the
next allowed level. The frequencies and intensities of absorbed infrared light depend on the
specific bond strengths and the geometrical shapes of the molecule. The absorption pattern
(called a spectrum) is unique for each material. The infrared spectrum is measured by either
absorbance or percent transmittance on the y-axis and by either the wavelength (μm) or
wavenumber (cm-1) to measure the position of an infrared absorption on the x-axis. Analysis of
this absorption spectrum reveals details about the molecular structure of the sample based on the
known symmetric and random vibrational modes of different atomic arrangements. This can be
very helpful in functionalization studies for scientific research. For example, the shifting or
disappearance of absorption bands in the spectrum of a given functional ligand can be evidence
to change in the functional group of the ligand. Although this technique does not typically give
conclusive evidence alone, it can be very powerful if used in conjunction with other data.
The main component in the FTIR spectrometer is an interferometer. The interferometer
consists of two mirrors and a beam splitter positioned at an angle of 45 degrees to the mirrors
which separate it into two beams. One will reflect from a fixed mirror in place and the other will
reflect from a moving mirror. The two beams are then reflected back and recombined at the
beam splitter with half of the light passing on toward the sampling areas and half travelling back
toward the source. The signal at the detector is a cosine wave.
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Figure 2-9: Block diagram of FTIR spectrometer
Fourier transform infrared (FTIR) spectroscopy was performed with Thermo Nicolet
NEXUS 670 FTIR attached to an attenuated total reflectance (ATR) accessory. ATR was fitted
with a single bounce diamond at 45° internally reflected incident light providing a sample area of
1 mm in diameter with a sampling depth of several microns. This accessory provides for the
non-destructive measurement of samples with little or no preparation. A small amount of the
sample was directly placed on the diamond disk and scanned for absorbance over the range from
4000 to 500 cm–1 wave numbers at a resolution of 1 cm–1.
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2.8. Ultraviolet-visible spectroscopy (UV-vis)
Ultraviolet visible spectroscopy measures the response of a sample to ultraviolet and
visible radiations region of electromagnetic spectrum. When the sample is irradiated with light
with wavelength in the UV-vis region, the molecular atoms undergoes electronic transitions from
the ground state to the higher excited state. These electronic transitions in organic compounds
can be explained by one of the following processes: σ to σ* transition that is present in
compounds containing single bonds. π to π* transition that takes place in compounds that
contain double bonds. n to σ* and π to π* transitions are present in compounds containing lonepair of electrons and a single or a double bond respectively. Also, d-d or f-f transitions in
inorganic compounds take place between a ground and an excited state of the d and f orbitals
respectively. The wavelength and amount of light that a compound absorbs depends on its
molecular structure and the concentration of the compound used.
Figure 2-10 shows the basic setup of the UV-vis spectrometer. A beam of light from a
visible and/or UV source passing through the diffraction grating where the light is separated into
its component wavelengths. Then the monochromatic light beam travels through the aperture,
which is an opening that determines the cone angle of the light rays that comes to focus in the
image plane. Finally the light passes through the sample before the materials absorption is
detected. In this work UV-vis spectroscopy was used to determine the folic acid conjugation to
the PLGA polymer. The UV-vis spectroscopy was performed on Hewlett Packard 8453 UVvisible Spectroscopy Systems.

51

Figure 2-10: Block diagram of the UV-vis spectrophotometer

Chapter 3. Iron oxide nanoparticles and their properties
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3.1. Iron oxide nanoparticles
Magnetic iron oxide nanoparticles are iron oxide particles with diameters between 1100 nanometers (nm). There are several different forms of iron oxide; however the three main
forms in which the iron oxide nanoparticles exist are magnetite ( FeIIFeIII2O4, ferrimagnetic),
maghemite (α-Fe2O3, ferrimagnetic), and hematite (γ- Fe2O3, weakly ferromagnetic or
antiferromagnetic).109,110 Magnetite has an inverse spinel structure with the divalent Fe2+ ion in
tetrahedral (A sites) coordination and the trivalent Fe3+ ions in octahedral (B sites) coordination
with oxygen as shown in Figure 3-1.111 Maghemite also have an inverse spinel structure like
magnetite in which each cell contains 32 oxygen ions, 21 1/3 Fe3+ ions and 2 1/3 vacancies.110
It differs from magnetite in that all or most of the iron are in the trivalent Fe3+ state and cations
are distributed randomly over the 8 tetrahedral and 16 octahedral sites.

Hematite has a

rhombohedral crystal structure with the trivalent Fe3+ ions in octahedral coordination with
oxygen.110 These nanoparticles can be synthesized using a variety of synthetic techniques such
as the sol-gel process, reverse micelles technique, chemical precipitation, hydrothermal
synthesis, polyol technique, and physical vapor deposition, and pyrolysis.112-117 All these
methods are well used procedures for nanoparticles preparation; however, the particles
produced by these techniques differ in the size, morphology, size distribution and magnetic
properties.110,116,118
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Figure 3-1: Drawing of the spinel structure illustrating the octahedral and tetrahedral
sites

3.2. Magnetism
Magnetic property in general sense arises from unpaired electron spins in outer shell, or
valence electrons of an atom. An Iron atom with 4 unpaired electrons in 3d shell has a strong
magnetic moment. Ions Fe2+ has also 4 unpaired electrons in 3d shell and Fe3+ has 5 unpaired
electrons in 3d shell. Therefore, when nanoparticles are formed from iron atoms or ions Fe2+
and Fe3+ they can be in ferromagnetic, antiferromagnetic, or ferrimagnetic states. A better
understanding of magnetism in general is an essential step on the way into understanding the
magnetism of these nanoparticles. The magnetic behavior of materials can be classified into
five major groups as shown in Table 3-1
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Types of
Magnetism

Diamagnetism

Applied magnetic field

Resultant effect




Repel the field
Negative magnetic
susceptibility




Align from the field
Small positive
magnetic
susceptibility




Align with the field
Large positive
magnetic
susceptibility



Half of the spins
align with the field
Divergence observed
in the magnetic
susceptibility

Paramagnetism

Ferromagnetism

Antiferromagnetism





Ferrimagnetism



Some spins align
with the field and
some did not
Positive magnetic
susceptibility

Table 3-1: Schematics of the five main types of magnetism seen in a material and their
response to the applied magnetic field. Paramagnetic, Ferromagnetic, and Ferrimagnetic
materials have net positive magnetic moment in the direction of the applied field.
Diamagnetic and Antiferromagnetic materials have a zero net moment.
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3.3.Diamagnetism and Paramagnetism
Diamagnetism refers to materials that are repelled from an applied magnetic field.
Diamagnetic material has paired electrons in their valence shell, leading to a net zero magnetic
moment. When an external field is applied a force is generated by the field that leads to
speeding up or slowing down of paired electrons. This leads to the change in the magnetic
moment of the orbital in a direction opposite to the external field. The spins in diamagnetic
materials align in an opposite direction to the field leading to negative magnetic susceptibility.
Paramagentism is the direct opposite of diamagnetism which takes on an alignment in
the direction of the applied magnetic field i.e. they are attracted to a magnetic field. In a
paramagnetic material, the spins of the electrons are not coupled and will have a resultant
magnetic moment. This moment tend to align with the applied magnetic field leading to a
small positive magnetic susceptibility. Paramagnetic materials have short range magnetic
order because they relax back to their original random state in the absence of magnetic field.
The other basic forms of magnetism- ferro, ferric and antiferro magnetism like paramagnetism
possess magnetic moment. The only difference to paramagnetic material is in the ability of
these magnetic materials to interact and couple with the applied magnetic field through
exchange coupling.

3.4. Exchange coupling
Exchange coupling is a quantum mechanical phenomenon arising due to the relative
orientation of the spins of two electrons. There are three types of exchange coupling by which
atomic spins in a material can interact. These are direct exchange, indirect exchange, and
superexchange that may produce either parallel or antiparallel exchange coupling.

Direct

exchange occurs due to quantum mechanical coupling between electrons of adjacent atoms.
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For example if a system involves two atoms, each with one electron and if the interatomic
distance is relatively small, the electrons will spend most of their time between the nuclei to
minimize Coulomb interactions. Pauli’s exclusion principle states that electrons in the same
space and time must possess opposite spins, as illustrated in Figure 3-2. This gives rise to
antiparallel alignment and therefore negative exchange.

Figure 3-2: Direct exchange coupling between the neighboring atoms leads to an
antiparallel alignment of the electrons. This is due to Pauli’s exclusion principle when the
electrons are located in the same space and time.
Indirect exchange coupling takes place when the interatomic distances are larger. The
electrons then tend to be away from each other to minimizing electron-electron repulsion. This
results in the parallel alignment or positive exchange as shown in Figure 3-3.

Figure 3-3: Indirect exchange coupling takes place due to larger interatomic distance
between the adjacent atoms leads to a parallel alignment
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Superexchange occurs between two atoms that are too far apart to be connected by
direct coupling, but are connected by some other nonmagnetic atom, such as oxygen. Fig. 3.4
shows a simple representation of superexchange between two spins connected by a common
nonmagnetic atom. Parallel or anti parallel alignment of the coupled electrons is dependent on
the distance and orientation or bond angles of the exchange. For example, the tetrahedral sites
in the spinel ferrite structure align anti-parallel to the octahedral sites via this superexchange
mechanism. The metal cations in the ferrites and metal oxides interact through superexchange.

Figure 3-4: Superexchange between two magnetic atoms through a nonmagnetic atom

3.5. Ferromagnetism, Ferrimagnetism and Antiferromagnetism
Ferromagnetic materials exhibit parallel alignment produced due to indirect coupling of
the electron spins. The electron spins in ferromagnetic materials align parallel to each other
within small regions of the material to form domains. In an un-magnetized state, the domains
are aligned at random so there is no overall magnetic effect. When an external magnetic field is
applied to the material, the domains align to point in the same direction, producing a strong
overall magnetic effect. Ferromagnetic materials tend to have long range ordering and show
high positive magnetic susceptibility.

While in antiferromagnetic materials the magnetic
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moments of atoms that are related to the spins of electrons, align in opposite direction to each
other due to direct exchange coupling.

Antiferromagnetic materials have zero net

magnetization as the magnetic moments equal in magnitude are aligned in opposite directions.
Ferrimagnetic materials magnetic moment is aligned antiparallel to each other as in
antiferromagnetic materials but the moments are unequal in magnitude and spontaneous
magnetization remains. The substances behave like ferromagnetic materials. Ferrimagnetism
is exhibited by ferrites and magnetic oxides.
Figure 3-5 represents the curve of the magnetization (alignment of the spins with
magnetic field) versus the applied field curve, commonly known as the M-H curves of
diamagnetic, paramagnetic, and ferromagnetic materials.

Diamagnetic materials show an

inverse relation between the applied field and the magnetization because the spins oppose the
direction of the applied field. While a direct relationship between the applied field and the
magnetization is seen for paramagnetic materials as their spins align with the field. As the
paramagnetic materials have short range magnetic ordering, no saturation magnetization (M s)
is observed. Saturation magnetization (M s) is described as the alignment of all the spins of the
particles with the applied external magnetic field.

Consequently they have zero remnant

magnetization (Mr) and zero corecivity (H c). Remnant magnetization (Mr) is the retention of
magnetization in the absence of an applied magnetic field and zero coercivity (H c) is defined as
the intensity of the applied magnet field required to reduce the magnetization of that material to
zero after the magnetization of the sample has been driven to saturation. The M-H curves for
ferromagnetic forms a hysteresis loop.

High magnetization saturation is reached in

ferromagnetic materials as the magnetic domains align with the applied field.

Thus,

ferromagnetic materials have a coercivity value higher than zero, because a certain amount of
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energy is needed to randomize the highly aligned domains.

They also retain magnetization

after the applied field is removed giving a positive remnant magnetization value.

Figure 3-5: The expected plot of magnetization vs. applied field for diamagnetic,
paramagnetic and ferromagnetic materials
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3.6. Superparamagnetism
In bulk ferromagnetic materials, when an external magnetic field is applied the
magnetic moments exhibit multi domain properties, each domain presents a group in which all
the atomic magnetic dipoles are spontaneously aligned. These magnetic domains are separated
by domain walls of ~100 nm width.

When the bulk magnetic materials are reduced to

nanoscale the width of the domain walls also reduces. Magnetic particles below a certain
diameter cannot support more than one domain and are thus described as single-domain.119
This diameter is termed as the critical diameter and is given by Eq. 3.1

3.1

Where A is the exchange constant, MS is the moment per unit volume and for typical
materials its value is 10–50 nm.119

At this size all the atomic magnetic moments are rigidly

aligned as a single giant spin and the magnetic behavior of the particles is defined as
superparamagnetism.117,119,120 When a high magnetic field is applied however, the spins align
with each other resulting in saturation of the magnetic moment (similar to ferromagnetism), but
when the magnetic field is removed, the magnetic moments undergoes magnetic relaxation
(similar to paramagnetism). The relaxation of the magnetization orientation of each particle is
determined by Eq. 3.2
3.2
Where τ is the relaxation time at one orientation, K is the particle’s anisotropy constant,
Vis the particle volume, k is the Boltzmann’s constant, and T is the temperature. As the size of
the particle decreases to a level where KV (free-energy barriers) becomes comparable to kT
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(thermal energy), its magnetization starts to fluctuate from one orientation to another, leaving
no coercivity and net magnetic moment.119,121 At this nanoscale the particle responds quickly
to an external magnetic field to reach saturation magnetization, while dropping back to zero
when the field is removed.
This superparamagnetic property of the iron oxide nanoparticles makes them very
attractive for potential applications in several fields, especially for biomedical applications
such as enhanced resolution magnetic resonance imaging (MRI), targeted drug delivery and
imaging,

hyperthermia,

magneto-transfections,

gene

therapy,

stem

cell

tracking,

molecular/cellular tracking, magnetic separation technologies (e.g. rapid DNA sequencing),
detection of liver and lymph node metastases. 122-124 The focus of this research is on designing
a dual modal imaging and therapeutic drug delivery system, so the role of superparamagnetic
iron oxide nanoparticles as contrast agents in MRI and heating agents in hyperthermia will be
discussed briefly in sections 3.3 and 3.4.

3.7. Magnetic resonance imaging (MRI) application
Magnetic resonance imaging (MRI) is a powerful tool for the diagnosis of disease and
the study of biological processes such as cancer metastasis and inflammation. MRI makes use
of the property of nuclear magnetic resonance (NMR) to image hydrogen nuclei inside the
body. The MRI image is constructed because of the difference in the rates of equilibrium
states of protons that are present in various environments (tissues). The protons in water and
tissue will align in a given direction (z-axis) when a static magnetic field is produced by the
MRI magnets. A radio frequency (RF) pulse at the resonance frequency (Larmor frequency)
is applied to the aligned protons which flips the spin of the aligned protons in the body. Once
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the Rf pulse is removed the excited protons begin to relax back to their original spin states
through longitudinal relaxation time (T 1) or transverse relaxation time (T 2). The spin lattice or
longitudinal relaxation time (T 1) describes the rate that nuclear spins return to equilibrium and
the spin–spin or transverse relaxation time (T 2) is the time constant that describes the rate of
signal decay. The MRI signal is governed by the concentration of protons and the nuclear
relaxation time, T1 and T2.125 The image contrast can be varied by adjusting the instrumental
parameters of the imaging process or by taking advantage of the intrinsic parameters such as
the local concentration of the hydrogen nuclei, relaxation parameters, and magnetic
susceptibility. Above all this the contrast of the image can be enhanced by intravenously
injecting contrast agents.126,127 MRI contrast agents alter the relaxation times of the tissues and
body cavities, and depending on the image weighting, it can give a higher or lower contrast
signal. Paramagnetic gadolinium (Gd) based particles are the most commonly used MRI
contrast agents, which shows a strong T1 shortening effect.128 However they have relatively
low contrast effects and a very short retention time in vivo.
biocompability

of

these

Gd

based

contrast

agents

are

Also the toxicity and
not

clearly

known. 129

Superparamagnetic iron oxide (Fe3O4 and Fe2O3) nanoparticles are gaining much attention as
MRI contrast agents.

123,130,131

Superparamagnetic iron oxide nanoparticles have high

magnetic moment which can cause microscopic field inhomogeneity and can activate the
dephasing of the protons. This makes them effective in reducing the T2 relaxation time, and
thereby leading to signal hypo- intensities in T2 or T2* weighted images. The image areas
containing iron oxide nanoparticles therefore induce a signal darkening on the MRI
images.109,132 The signal void due to the large magnetic susceptibility of the nanoparticles is
much larger than the nanoparticle size, thus enhancing the detectability. Designing these
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nanoparticles with targeting specificity, the negative contrast alterations can be harnessed to
report abnormal biological activity.

3.8. Magnetic hyperthermia
Hyperthermia can be defined as controlled temperature elevation by targeting the
heating field to the malignant tumors as well as the surrounding tissue, organ, part of body or
even to the whole body. The use of hyperthermia in the treatment of malignant tumors is wellknown since ancient times. Hippocrates, the father of medicine had proposed that surface
tumors can be treated by the application of hot iron.133 Hyperthermia is a promising form of
cancer therapy alongside of the typical methods of surgery, chemotherapy and radiotherapy.
Hyperthermia takes the advantage of the cancerous cells being more sensitive to higher
temperatures in the ranged of 42-45º C than the healthy cells. The tumor cells could be killed
by necrosis if the temperature is above 45º C, or could it can help improve the efficiency of
chemotherapy if the temperature is raised around 42º C.134
Magnetic iron oxide nanoparticles act as mediators and help induce heat to the tumors.
When these nanoparticles are exposed to an external alternating current (AC) magnetic field,
some heat is generated due to magnetic hysteresis loss. These losses, depending upon the
thermal conductivity and heat capacity of the surrounding medium are dissipated in the form of
heat; raising the temperature of the surrounding. The amount of heat generated depends on the
nature of the magnetic particles and the external field applied.

The heat dissipated by a

magnetic nanoparticles subjected to an AC magnetic field is given by specific absorption rate
(SAR), which is described as shown in Eq. 3.3. SAR is expressed in W/g of nanoparticles.
3.3
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Where C is the specific heat capacity of the sample and T and t are the temperature and
time, respectively.135,136 SAR is very sensitive to the material properties. In multi-domain
particles the heat is generated mainly due to magnetic hysteresis loss, but it is different for
small, single domain particles. As the size is reduced the particles shows superparamagnetic
behavior and would not exhibit hysteresis loss.

The two main contributing mechanisms of

SAR in single domain superparamagnetic nanoparticles are the Néel relaxation and Brownian
relaxation.

Néel relaxation is the random flipping of the spin without rotation of the

nanoparticle and depends on the magnetic property of the nanoparticles. The Néel relaxation
mechanism is analogous to the hysteresis loss in multi-domain magnetic particles whereby
there is an internal friction due to the movement of the magnetic moment in an applied external
magnetic field that results in heat generation. In Néel relaxation the moment alignment occurs
via the usual Stoner–Wohlfarth process subject to thermal activation where the relaxation time
is given by Eq. 3.4.
(

)

3.4

Where τN is the Néel relaxation time, τ0 is the average relaxation time in response to a
thermal fluctuation and is typically in the order of a few nanoseconds, k is the Boltzmann
constant, T is the temperature and ∆E is the energy.
Brownian relaxation is the rotation of the entire nanoparticle within the fluid medium
and depends on the viscosity of the medium as shown in Figure 3-6.133,136,137 In Brownian
relaxation the moment can align with the ﬁeld by physical rotation with a relaxation time given
by Eq.3.5
3.5
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Where η is the viscosity coefficient of the fluid, k is the Boltzmann constant, VH is the
hydrodynamic volume, T is the temperature, and τB is the Brownian relaxation time.

Figure 3-6: Schematic representation of relaxations of magnetic particles either through
spin rotation (Neel) or particle rotation (Brownian), when the particles are exposed to an
AC magnetic field. Néel relaxation is the random flipping of the spin without rotation of
the nanoparticle while the Brownian relaxation is the entire rotation of the nanoparticle
in the fluid.

Chapter 4. Poly (styrene-co-vinylbenzylchloride-co-divinylbenzene)
(PSVBDVB) composites containing magnetic iron oxide
nanoparticles
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4.1. Overview
Polymeric nanocomposites have evolved as a potential tool for the design of an ideal drug
delivery system (DDS) for cancer treatments. Both imaging and therapeutic agents can be
encapsulated within the polymeric nanocomposites through various techniques as discussed in
chapter 1. In this project magnetic iron oxide nanoparticles have been used as a dual modal
imaging (contrast agents for MRI) and therapeutic agent (heat mediators in hyperthermia), which
are encapsulated into poly (styrene-co-vinylbenzylchloride-co-divinylbenzene) (PSVBDVB)
polymer.79
The key step in the design of a dual modal drug delivery system is the encapsulation of
the magnetic iron oxide nanoparticles with polymer of choice.

A proper understanding of

possible synthetic anomalies that arise from the inclusion of nanoparticles within the polymer
during synthesis is necessary. It is also very important to investigate the dilution effect of the
saturation magnetization of the iron oxide nanoparticles due to the polymer coating. Different
types of polymer coating have been investigated and the choice of the appropriate one depends
on many factors and principally on the clinical purposes of the functionalized nanoparticle. The
most commonly polymer coating used for biocompatible iron oxide nanoparticles is derivatives
of dextran.138,139 The association of dextran with iron oxide has led to its widespread use as a
coating for iron oxide NPs for many decades. However, either dextran or nanoparticles made
with dextran can cause anaphylactic reactions.

Also the dextran coating is found to be

biologically unstable and leads to sedimentation and aggregation of the iron oxide
nanoparticles.140

Therefore it is desirable that the magnetic nanoparticles be efficiently

encapsulated into a robust polymer.
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To study these synthetic variations upon encapsulation with a polymer, the magnetic iron
oxide nanoparticles were encapsulated into a robust poly (styrene-co-vinylbenzylchloride-codivinylbenzene) (PSVBDVB).79

PSVBDVB is a copolymer of styrene, vinylbenzylchloride

(VB) and divinylbenzene (DVB) and their structures are shown in Figure 4-1. Polystyrene
copolymer is biocompatible, cheap, well-known, and can be easily functionalized by
copolymerization. Also the polymerization process for the synthesis of polystyrene is very well
established.141 Furthermore the encapsulation of iron oxide nanoparticles within the polymer can
be carried out by polymerization process, which ensures a homogenous distribution of the
nanoparticles within the composites. The cross linking agent divinylbenzene (DVB) was used
to impart better mechanical strength to the polymeric composites, as compared to styrene alone.
Vinylbenzylchloride (VB) confers a hydrophilic group to the composites which makes it possible
for use in a wider range of applications like drug delivery, column separation technique. The
only difference to styrene is that VB contains chlorine to the para position to the vinyl group so it
would not interfere in the polymerization process and good distribution of VB would be
obtained. Also addition of VB allows for the functionalization of the magnetic composites at the
chlorine site through nucleophilic substitution reactions.

Figure 4-1: Structure of styrene, vinylbenzylchloride (VB) and divinylbenzene (DVB)
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4.2. Synthesis
The first step in the synthesis of PSVBDVB composites containing the iron oxide
nanoparticles is the synthesis of mono-dispersed iron oxide nanoparticles. In order to prepare
iron oxide nanoparticles with uniform size and shape, it is necessary to control the kinetics of
their nucleation and growth. The best control is achieved when the nucleation and growth steps
are separated. There are numerous methods of iron oxide nanoparticle synthesis such as coprecipitation method, polyol technique, reverse micelles technique, sol gel technique,
hydrothermal synthesis, chemical and physical vapor deposition, and pyrolysis. 114,142-144 Polyol
technique is a simpler synthetic technique that allows for the control over the nucleation and
growth events and will be discussed in detail in section 4.2.1
The next step is the synthesis of the PSVBDVB composites with iron oxide
nanoparticles.

To properly understand the possible synthetic anomaly that arises from the

inclusion of nanoparticles within the polymer during synthesis. A homogenous polymer coating
is desirable for magnetic nanoparticle encapsulation.

For this reason precipitation

polymerization technique was employed for the formations of PSVBDVB composite, where in
the polymeric composites are synthesized from its monomers. PSVBDVB as discussed earlier is
a copolymer of polystyrene. Conventional methods for the synthesis of the copolymers are
dispersion polymerization, suspension polymerization, and emulsion polymerization. Monodispersed sub-micron sized polymeric composites with a highly cross linked structure cannot be
obtained by these processes. Precipitation polymerization was thus utilized to synthesize highly
cross linked polystyrene copolymers.145,146 It is a very simple and versatile polymerization
technique

yielding

mono-dispersed

spherical

polymeric

polymerization will be discussed in detail in section 4.2.2

composites.

Precipitation
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4.2.1. Synthesis of magnetic Iron oxide nanoparticles by Polyol technique
Iron oxide nanoparticles were synthesized by polyol technique similar to those found in
the literature.115,147,148 The polyol technique refers to the use of a polyalcohol (polyol) to reduce
the metal precursor. The polyalcohol used acts as a solvent as well as when coupled with a base
serves as a mild reducing agent.115 In this technique, a solid inorganic precursor is suspended in
a liquid polyol along with a base. The suspension is stirred and heated to a given temperature,
leading to super-saturation of the solution. Consequently a short nucleation burst will occur
followed by a slow growth of the metallic particles. 115 The starting materials can range from
metal hydroxides, nitrates, chlorides to acetates. The reduction of metal precursors can be
achieved in various polyols such as ethylene glycol, propylene glycol, diethylene glycol,
trimethylene glycol, butylene glycol, and trimethylene glycol. The polyol technique produces
finely dispersed, non-agglomerated metal nanoparticles with well-defined morphology, narrow
size distribution and high crystallinity. The main advantage of polyol technique over other
synthetic routes is that the polyol solvent also act as a protective layer preventing particles
aggregation and passivates the nanoparticles against oxidation.
The synthesis of the iron oxide nanoparticles was carried out by polyol technique as
shown in Figure 4-2. 0.40 g of Iron (II) acetate was slowly added to 25.00 mL ethylene glycol
under magnetic stirring. After the metal precursor was completely dissolved 1.00 g of sodium
hydroxide (NaOH) was added and the reaction solution was quickly heated to reflux under
magnetic stirring for 1 hour. The initial reddish-brown solution turned black at the end of 1 hour
reflux.

The iron oxide nanoparticles were then magnetically extracted and further washed

several times with methanol. In order to prepare the particles for the polymerization coating
process, two further washes and extractions were performed with anhydrous acetonitrile and
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sonication to remove any surface water, methanol, or glycol. After the last acetonitrile wash, the
particles were dried in a vacuum oven and kept under vacuum until further use.

Figure 4-2: Synthesis of Iron oxide nanoparticles by Polyol technique
4.2.2. Encapsulation of magnetic iron oxide nanoparticles with in the Poly (styrene-covinylbenzylchloride-co-divinylbenzene) (PSVDVB) composites
Precipitation polymerization was carried out by similar methods used to produce poly
(styrene-co-divinylbenzene) microspheres with the addition of vinylbenzylchloride in place of
some styrene monomer.141,149

Precipitation polymerization technique is a heterogeneous

polymerization process that starts with a homogeneous system in the continuous phase, where
the monomers and initiator are completely soluble, but upon initiation the formed polymer is
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insoluble and thus precipitates outs.150 During polymerization, the growing polymer chains
phase-separate from the continuous medium by entropic precipitation as the cross-linking
prevents polymer and solvent from freely mixing. 151

The uniqueness of precipitation

polymerization is the absence of polymeric stabilizer which is the key element in other
polymerization processes. The PSVBDVB composites containing iron oxide nanoparticles were
synthesized as below.
Styrene and divinylbenzene (DVB) monomers were treated with 0.10 M sodium
hydroxide solution to remove the inhibitor. Vinylbenzylchloride (VB) and azobisisobutyronitril
(AIBN) were used as received. AIBN is used as an initiator for the polymerization process to
start. The polymer composites were synthesized with monomer percentages of 30% styrene,
25% vinylbenzylchloride, and 45% divinylbenzene as shown in Figure 4-3. The iron oxide
nanoparticles were added to 1.00 mL of monomer solution at mass percentages of 0%, 1%, 3%,
and 5%, which was then placed under sonication to achieve a homogeneous dispersion of the
particles in the monomer solution. The monomer solution or the particle/monomer solution was
taken in a 250 mL round bottom flask equipped with a reflux condenser under N 2 atmosphere,
and then 50.00 mL of anhydrous acetonitrile was added as the solvent. The reaction mixture was
stirred mechanically at the rate of 60 rpm. Then 20.00 mg of AIBN (initiator) was added to the
reaction solution and the solution was heated to 75°C to initiate the polymerization process.
Once the temperature was stabilized at 75°C, the reflux condenser was capped with a balloon to
maintain the reaction under N2, and the reaction was allowed to age for 24 h. The reaction was
then quenched in “cold” methanol (~-20ºC) to precipitate the spherical polymeric composites.
Vacuum filtration was employed for the polymeric composites without the magnetic
nanoparticles and magnetic separation was employed for iron oxide nanoparticle loaded
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polymeric composite samples followed by further drying under vacuum to obtain the final
product.

Figure 4-3: Structure of Poly (styrene-co-vinylbebzylchloride-co-divinylbenzene) along
with its monomer content

4.3. Result and discussion
The PSVDVB coated magnetic iron oxide nanoparticles were characterized using a
variety of analytical techniques including scanning electron microscopy (SEM), thermal
gravimetric analysis (TGA), X-ray powder diffraction (XRD), and vibrating sample
magnetometer (VSM).
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Scanning electron microscopy (SEM) was performed on the polymeric composites, with
and without the magnetic iron oxide nanoparticles loading. The SEM samples were prepared by
lightly sprinkling the composite powder on a conductive carbon tape mounted on the sample
holder. The sample was then sputtered with gold to make it conductive and reduce charging.
The PSVBDVB composites without the iron oxide nanoparticle loading were spherical and
mainly mono dispersed and had a mean diameter of 3 μm as seen in Figure 4-4 (a). With
addition of 1% iron oxide nanoparticles by mass a decrease in the size of the polymeric
composites to a mean diameter of 2 μm was observed, as well as an increase in the polydispersity of the composites was seen as shown in Figure 4-4 (b). With further increase in the
ratio of iron oxide nanoparticles the size of the polymeric composites decreases and polydispersity of the composites increases. The difference in these samples can be explained if the
particles act as nucleation sites for the polymer chains. In the case without particles, the number
of polymer chains should be somewhat proportional to the amount of initiator. Then with a
uniform amount of chains being connected by cross-linker (DVB), uniformly sized composites
are achieved. When the nanoparticles are added, this gives a site for the monomers and forming
polymer chains to orient or nucleate. This causes the DVB cross-linking agent to be used more
quickly because the polymer chains are closer together, especially since the DVB has been found
to be more reactive than the styrene monomer in the typical polymer synthesis. 152 It also uses
more monomers around the surface of the nanoparticles due to their high surface area, thus
shortening the overall length of the polymer.
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Figure 4-4: (a) SEM image of as synthesized polymer beads without nanoparticle, (b) 1%
by mass nanoparticle to polymer reaction

Figure 4-5: Histograms of size measurements from SEM images of nanocomposites with
varying nanoparticle loading percentages.
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This trend in size reduction is seen to continue as more nanoparticles are added to the
system. The diameters of the spheres obtained are 3 ± 0.15 μm for 0% nanoparticles, 2 ± 0.30
μm for 1%, 1 ±0.35 μm for 3%, and 0.5 ± 0.15 μm for 5%, and are shown in Figure 4-5.

Figure 4-6: TGA plot showing decomposition profiles for the nanocomposites and polymer
beads
Thermal gravimetric analysis (TGA) was used to investigate the composition of the
composites formed. The PSVBDVB composites without the iron oxide nanoparticle loading
show a major decomposition event around 350 ºC corresponding to the decomposition of the
PSVBDVB copolymer. As can be seen in Figure 4-6 the 0% loaded sample has a smooth
decomposition profile with one primary decomposition temperature around 350 ºC. As the
nanoparticle loading is increased to 1%, the first major decomposition event is observed around
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440º C which is indicative of higher levels of cross linking between the monomers or greater
density copolymer formation. There is also an addition decomposition event at around 720º C
that is not present in the unloaded PSVBDVB composites and is attributed to the decomposition
of the sample impurities on the surface of the iron oxide nanoparticles.

Increasing to 3%

nanoparticles loading the decomposition profile is similar to 1%, with slight differences in the
later decomposition event around 700º C again attributed to decomposition of sample inpurities
on the surface of nanoparticles.. Then upon increasing to 5% loading, a third decomposition
event is observed at around 500º C attributed to the decomposition of the high density
PSVBDVB copolymer. The increase in the decomposition temperature and the decomposition
events is observed with increase in the nanoparticles loading. As the nanoparticle loading
increases, DVB is used up quickly as the nucleation sites increases. This causing a non-uniform
composition polymer formation due to the rapid utilization of the monomers, which is evident
from the difference in the decomposition profiles.
The powder XRD pattern of the as-synthesized iron oxide nanoparticles shows an inverse
spinel iron oxide phase with no impurities.

Figure 4-7 shows XRD patterns of the as-

synthesized iron oxide nanoparticles with an overlay of the data obtained from the JSPDS
reference powder diffraction patterns of maghemite (α-Fe2O3). By comparing the reference
diffraction pattern to the collected data, it is clear that the raw data is a representation of
maghemite.

The most intense peaks at 30.266º, 35.651º, 43.33º, 50.044 º, 53.766º, 57.319º,

62.949º, 71.430º, 74.493º 2θ corresponds to the (220), (311), (400), (421), (422), (511),
(440),(620), and (533) planes in the maghemite crystal structure. The peaks were indexed by the
JCPDS database for maghemite (p4332, card#01-089-5892)
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Figure 4-7: XRD pattern of the as-synthesized iron oxide nanoparticles with an overlay of
the data obtained from the JSPDS reference powder diffraction pattern of maghemite.
Magnetic characterization was performed by vibrating sample magnetometer (VSM) to
confirm that the composites synthesized were indeed magnetic and that the magnetization of iron
oxide nanoparticles was retained post polymerization. Figure 4-8 shows a hysteresis plot of the
as synthesized iron oxide nanoparticles and the composites with 5% nanoparticles loading, both
measured at room temperature. As can be seen, the saturation magnetization of the iron oxide
nanoparticles was 62 emu/g and is considered high since bulk maghemite has a magnetization
saturation range of 80-100 emu/g. The saturation magnetization of the iron oxide nanoparticles
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after polymerization was 6 emu/g and the reduction in the saturation magnetization is due to the
magnetic dilution due to the polymeric coating. Utilizing the TGA data for mass correction of
the polymer composite sample yielded a magnetization of 60 emu/g of iron oxide in the sample.
This shows that the iron oxide nanoparticles remained unchanged during the polymerization
process and no significant change is observed on the magnetization of the nanoparticles. Both
samples showed a coercivity of roughly 10 Oe at room temperature.

Figure 4-8: Plot of magnetization vs applied field for the as synthesized iron oxide
nanoparticles and the nanocomposite synthesized with 5% loading of the iron oxide
nanoparticle
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4.4.Conclusion
These results discussed indicates that the iron oxide nanoparticles are not just
incorporated into the polymer matrix but act as nucleation sites for the polymerization process to
begin. Although the polymerization process was found to have no effect on the magnetization of
the nanoparticles, the nanoparticles had several effects on the resultant polymer composites size
and morphology by decreasing the diameter, increasing the polydispersity, and decreasing the
uniformity of the polymer composition. These effects of nanoparticle loading reported give
insight into parameters that may need to be adjusted in order to obtain similar polymer sizes,
composition, and mechanical properties as nanoparticle loading is increased.
The encapsulation of magnetic iron oxide nanoparticles in the PSVDVB polymer was
achieved, but the magnetic PSVDVB composites cannot be utilized for drug delivery
applications. PSVDVB polymer is a non-biodegradable polymer. The polymeric composites if
introduced parenterally in the body will need to be surgically removed as the polymeric
composites will not disintegrate within the body. 153

Due to its non-biodegradability the

PSVDVB composites are not suitable for drug delivery applications. Thus, there is a need of a
robust biocompatible and biodegradable polymer that can be used for biomedical purposes and
will be discussed in chapter 5.
But the PSVBDVB composites with iron oxide nanoparticles can be used for cell
separations and as adsorbent for chromatography.154-156 These application of polymer coated
iron oxide nanoparticles will be discussed in chapter 7.

Chapter 5. Poly (D, L-lactide-co-glycolide) microcomposite containing
magnetic iron core nanoparticles as a drug carrier
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5.1. Overview
An appropriate selection of the polymer matrix is necessary in order to develop a
successful drug delivery system. The polymer can be non-biodegradable or biodegradable. But
as discussed earlier the major disadvantage with non-biodegradable polymers is that a surgery is
required to harvest these polymers out of the body once they are depleted of the drug. Hence,
non-degradable polymers can be used only if removal of the implant is easy.153 On other hand
biodegradable polymers either synthetic or natural, are capable of being cleaved into
biocompatible byproducts through chemical or enzyme-catalyzed hydrolysis.157,158 This
biodegradable property makes it possible to inject them into the body without the need of
subsequent removal by the surgical operation. 153 Drug delivery systems formulated with these
polymers can be released in a controlled manner, by which the drug concentration in the target
site is maintained within the therapeutic window. Biodegradation of polymeric biomaterials
involves cleavage of hydrolytically or enzymatically sensitive bonds in a polymer, leading to
polymer erosion.

The erosion of the polymer matrix is usually classified into two categories:

bulk (or homogeneous) erosion and surface (or heterogeneous) erosion. 159 Bulk erosion occurs
when the rate at which water penetrates into the polymer exceeds the rate at which the polymer is
converted into water soluble materials (monomers), resulting in erosion. 160 The size of the
polymeric composites remains almost constant in bulk erosion.

While surface degradation

occurs when the rate at which the polymer penetrates the device is slower than the rate of
conversion of the polymer into water soluble materials as shown in Figure 5-1.160 The rate of
degradation of biodegradable polymers is dependent on their hydrophilicity, and on the
accessibility of their hydrolytic unstable bonds to water and to specific enzymes that can break
these chemical bonds.

Consequently, the water uptake capability of the material, its

84

morphology, crystallinity, and molecular weight are key parameters that determine the
degradation kinetics of the polymer.

Figure 5-1: Schematic representation of bulk and surface erosion. In bulk erosion the
degradation takes place throughout the polymer surface, while surface erosion results in
the thinning of the polymeric particle.

5.1.1. Natural polymers
Early research into biodegradable polymeric DDS was mainly focused on naturally
occurring polymers like the proteins such as collagen, gelatin, and albumin and polysaccharides
such as glucose, dextran, starch, and chitosan.161 The chemical structures of naturally occurring
polymers are shown in Figure 5-2. The application of proteins for drug delivery has been limited
due to their low mechanical stability and high cost. On the contrary polysaccharides have
attracted researchers as they are commercially available at low cost and can be modified by
simple chemical reactions for specific applications. Chitosan a type of polysaccharide has been
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much researched as

it

has shown excellent

biocompability,

biodegradability,

low

immunogenicity and biological activity. These naturally occurring polymers mostly undergo
degradation through enzymatic bond cleavage.

Figure 5-2: Chemical structures of naturally occurring biodegradable polymers

86

5.1.2. Synthetic polymers
Recently the research focus into biodegradable polymeric DDS has shifted on to synthetic
polymers as they offer the advantage of tailoring the degradation process.

For synthetic

polymers, passive hydrolysis is the primary mode of degradation. In case of degradation by
hydrolysis, bulk degradation takes place and can be controlled by applying control over the rate
of water penetration and material swelling, which is governed by the hydrophilicity of the
polymer.162,163 Some of the synthetic polymer used for DDS are poly(ortho esters) (POE),
polyanhydrides, polyphosphazenes, and aliphatic polyesters.161

Figure 5-3: Chemical structures of the four generations of poly(ortho)esters (POE)
Poly(ortho)esters (POE) have evolved through four generation as biodegradable polymers
and their structures are shown in Figure 5-3.164 However, only the third and fourth generations
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POEs are semisolid and suitable for the manufacturing of a drug delivery system relevant for
clinical use. They are easy to manufacture and are characterized by faster degradation rates
compared to polyesters.165 POEs have a degradation span of several days to several months.
POEs undergo surface erosion because of high hydrophobicity and water impermeability. 165 In
POE composites the drug release and surface erosion of the polymer takes place simultaneously.
Polyanhydrides have been investigated for short term drug release as they undergo rapid
degradation in vivo and have poor mechanical properties. 166,167 Their main advantage is that they
contain the most reactive anhydride groups available for degradation.

Polyanhydrides are

known to also undergo surface erosion and their degradation rate can be manipulated by varying
the polymer composition.168 The main drawback of these polymers is that they need to be kept
frozen under anhydrous conditions because of the dynamic hydrolysis of the anhydride bond.
Polyanhydrides have a degradation spam of few days to few weeks.
Polyphosphazenes are liner polymers composed of an inorganic backbone with nitrogen
and phosphorous atoms.169 These polymers can be modified readily by manipulating either the
backbone or the side chain, thus enabling the tuning of their degradation rate. These polymers in
presence of water cleave into nontoxic, low molecular weight products such as phosphates, and
ammonia. Polyphosphazenes can degrade by both bulk and surface erosion depending on the
accessibility of the bonds and hydrophobicity of the polymer.170
Aliphatic polyesters with hydrolysable backbones are promising candidates for control
release DDS. This class of polymers degrades via the hydrolytic cleavage of the ester bonds in
their backbone. While the role of enzymatic degradation for this class of polymers is not clearly
understood.

Some of the widely used aliphatic polyesters are poly(lactide) (PLA),

poly(glycolide) (PGA) and the copolymer of PLA and PGA- poly (lactide-co-glycolide) (PLGA)
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and their structures are shown in Figure 5-4. These polymers have been used in biomedical
applications for more than 20 years and are known to be biodegradable, biocompatible and nontoxic, and are approved by FDA (Food and Drug Administration) for human applications.

Figure 5-4: Chemical structure of polyesters

Poly(lactide) and Poly(glycolide) are polymer formed by ring opening polymerization of
lactic acid and glycolic acid respectively. 171 They both belong to the α-hydroxy polymer family
and degrade by the hydrolysis of the ester linkage to produce the respective monomers- lactic
acid and glycolic acid. Both of these polymers have been extensively researched as appropriate
candidates for drug delivery matrixes. PLA has three forms due to the presence of a chiral center
D(-), L(+), and racemic (DL) forms.

PGA degrades easily as it is more hydrophilic in nature

due to the absence of the methyl groups while on other hand PLA is found to be more robust in
the body.172

PLA takes the longest to degrade biologically, with a biodegradation time of more
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than two years while PGA biodegrades relatively quickly, in only two to three month. Because
these polymers vary differently in the biodegradation time, their copolymers can be synthesized
with a wide-variety of degradation times, depending on the application.

5.2. Poly (lactide-co-glycolide) (PLGA)
Poly (lactide-co-glycolide) (PLGA) is a copolymer of lactide and glycolide, and is
synthesized by random ring opening co-polymerization process. Commonly used catalyst for the
co-polymerization process are tin(II)2-ethylhexanoate, tin(II) alkoxides, and aluminium
isopropoxide. In the co-polymerization process the monomers- lactide and glycolide are linked
together by ester linkage yielding a linear, amorphous PLGA polymer as shown in Figure 5-5.

Figure 5-5: Ring opening co-polymerization process of lactide and glycolide in presence of
catalyst to obtain PLGA
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The forms of the PLGA are identified by the composition of the monomer used such as
PLGA 50:50 or PLGA 75:25. The degradation rate and the mechanical properties of the polymer
can be influence by varying the monomer ratio (ratio of lactide: glycolide) and by controlling the
monomer stereochemistry, molecular weight, and degree of polydispersity. For example PLGA
50:50 has the fastest degradation time of about 50-60 days and likewise PLGA 65:35, 75:25,
80:20, and 90:10 have progressively longer degradation time. 173

PLGA undergoes bulk

degradation through random hydrolysis of the backbone ester linkage in presence of water to
produce the original monomers. The degraded monomers- lactic acid and glycolic acid are
easily metabolized into the body via the Krebs cycle and are eliminated. 174

Thus there is

minimal systemic toxicity associated with using PLGA for biomedical applications. Also the
original shape and mass of the polymer is preserved until 90% degradation has occurred. The
general properties and degradation rate of PLGA, PLA and PGA are summarized in Table 5-1.
Polymer
PGA
PLLA

Crystallinity
Highly
crystalline
Semicrystalline

Tg (ºC)

Degradation
rate

35-40

2-3 months

60-65

˃ 2 years

PDLLA

Amorphous

55-60

12-16 months

PLGA

Amorphous

45-55

1-6 months

Table 5-1: General properties of the polyester polymers- PGA, PLLA, PDLLA, PLGA and
their respective degradation rates
PLGA composites can be synthesized by various techniques such as emulsification
solvent evaporation technique, salting out, spray drying, nano-precipitation techniques as
discussed in chapter 1. The emulsion solvent evaporation technique is the most frequently used
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to produce polymeric composites. This technique is simplest of all and encapsulation of the
therapeutic and imaging agent can be carried out with ease. The physical properties of obtained
composites are strongly dependent on the nature of materials and also on the parameters during
the manufacturing of the composites.
This chapter focuses on the preparation of biodegradable and biocompatible PLGA
composites for drug delivery applications. 78 For this work the emulsion solvent evaporation
technique was used to produce the PLGA composites containing the metallic iron nanoparticles
and ruthenium dye as the drug analog. The iron-iron oxide core shell nanoparticles (Fe@FeOx)
were used as imaging and heating agents as discussed earlier. Fe@FeOx core shell nanoparticles
were used instead of iron oxide nanoparticles as they possess superior magnetic properties due to
the formation of metallic iron core. The Fe@FeOx core shell nanoparticles were synthesized by
reverse micelle technique and will be discussed in synthetic section.

5.3. Tris-(2,2'bipyridyl)dichlororuthenium (II) [Ru(bpy) 3]2+ dye

Figure 5-6: Chemical structure of Tris-(2,2'bipyridyl)dichlororuthenium (II) [Ru(bpy)]
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Tris-(2,2'bipyridyl)dichlororuthenium (II) [Ru(bpy) 3]2+ is a ruthenium based metal
complex dye, and its structure is as shown in Figure 5-6. It is a red crystalline salt obtained as a
hexahydrate. Ru(bpy) was used as the drug analog, as it is a fluorescent dye so its release from
the polymeric composites can be easily monitored through fluorescence spectroscopy. In
aqueous solution the [Ru(bpy)3]2+ cation has an excitation wavelength of 470 (±3) nm. Due to
the absorption of visible light by [Ru(bpy) 3]2+ leads to the formation of the charge transfer
excited state *[Ru(bpy)3]2+ as shown in Eq. 5-1
[Ru(bpy)3]2+ + hv

*[Ru(bpy)3]2+

5-1

The excited state has a life time of about 890 nano seconds and then relaxes back to the
ground state by emission of photons at a wavelength of 610 nm as shown in Eq. 5-2.
*[Ru(bpy)3]2+

[Ru(bpy)3]2+ + hv’

5-2

However, if a quencher is present, the excited state will decay to the ground state more rapidly
due to the formation of electron transfer complex. The reaction can be shown as in Eq. 5-3.175
*[Ru(bpy)3]2+ + Q(n)+

[Ru(bpy)3]2+ + Q*

5-3

The excited *Ru(bpy)3 can act as both electron donor and electron acceptor species. A
variety of inorganic and organic species such as metal ions, and oxygen can act as quenchers. 176
The efficiency of the electron transfer quenching is governed my factors such as distance
between the donor and acceptor, degree of quantum mechanical coupling between the molecular
orbitals of donor and acceptor as well as the free energy change (∆Gº) for the reaction. 177,178
In this work the fluorescent Ru(bpy) dye was used as drug analog to study its
release from the PLGA composites when irradiated with microwave radiation. The Fe@FeOx
nanoparticles quench the fluorescence of the Ru(bpy) dye through charge transfer quenching.
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The Fe@FeOx nanoparticles and the Ru(bpy) dye are closely packed within the composites so
the donor acceptor distance is reduced thus increasing the rate of charge transfer.

5.4. Synthesis
Iron-iron oxide core shell nanoparticles (Fe@FeOx) nanoparticles were synthesized by
reverse micelle technique. Before describing the reverse micelle synthetic technique a brief
overview of the technique will be provided in section 5.3.1. The PLGA composites with the
Fe@FeOx nanoparticles and the dye were prepared by emulsion solvent evaporation technique
and will be discussed in section 5.3.3. PolyD,L-lactide-co-glycolide 50:50 i.v (PLGA) was
obtained from Polysciences, Inc. Poly (vinyl alcohol) (PVA) 88% hydrolyzed with an average
molecular weight of 88,000 and anhydrous dichloromethane (DCM) were purchased from Arcos
organics. Tris-(2,2'bipyridyl)dichlororuthenium (II) [Ru(bpy)3Cl2·6H2O] was purchased from
Sigma Aldrich. All chemicals were used as received without further purification
5.4.1. Overview of Reverse micelle technique
Reverse micelle technique has been utilized to synthesis the iron-iron oxide core shell
nanoparticles. The main advantage of this technique is that the size distribution can be improved
even in room temperature reactions. Normally if the reaction is carried out at room temperature,
the nucleation and growth events compete greatly expanding the size distribution of
nanoparticles synthesized. It is also cost effective, fast reaction requiring simple equipment and
it does not require temperature or pressure control. The reverse micelles isolate reactants from
one another, thereby better regulating the nucleation and growth at lower temperatures. A proper
understanding of the reverse micelle and the processes involved is essential.
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Figure 5-7: Schematic representation of water in oil reverse micelle (right) and oil in water
micelle (left)

Micelles are formed when an oil phase, aqueous phase, and the surfactant are mixed in a
proper proportion. The surfactant is required to have an affinity for both the aqueous and oil
phases, and it acts to provide the barrier between the primarily immiscible phases. Micelles are
formed when the concentration of the surfactant exceeds the critical micelles concentration
(CMC) in water. There are several types of surfactant used for reverse micelles that can be
categorized into four groups: cationic, anionic, nonionic and zwitterionic.

In normal micelles

the surfactant’s hydrophobic tail is directed toward the interior part and the hydrophilic head is
directed towards the surrounding aqueous phase. Alternatively, in reverse micelles, the
hydrophilic head of the surfactant is directed towards the interior of the micelles and the
hydrophobic tail is directed to the oil phase. Figure 5-7 shows the difference between normal
micelles (left) and reverse micelles (right). The reverse micelle droplets that are formed act as
nano-reaction vessels in which the nanoparticles synthesis can be carried out. The size of the
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nanoparticles formed can be controlled by controlling the size of the formed reverse micelles.
The reverse micelles can also exist as dimers for nanoseconds during which some exchange of
materials between the micelles takes place allowing for sequential synthesis techniques.179 Also
as the reverse micelle reaction takes place in aqueous media, so variety of chemical reactions
such as oxidation- reduction, co-precipitation, and substitution reaction can be easily carried
out.114
5.4.2.Iron-iron oxide (Fe@FeOx) core shell nanoparticles synthesis via reverse micelle
Iron-iron oxide (Fe@FeOx) core shell nanoparticles were synthesized via reverse micelle
techniques under nitrogen using Schlenk line techniques as found in the literature.180,181

The

surfactants used for this synthesis were nonylphenoxy poly(ethyleneoxy)ethanols with differing
head group repeating units of 9 and 5 as surfactant and co-surfactant (NP9/NP5) sold by Rhodia
Incorporated under the name Igepal CO-520 and CO-630 as shown in Figure 5-8. Cyclohexane
was used as the solvent.

Figure 5-8: Nonylphenoxypoly(ethyleneoxy)ethanols abbreviated as (NP). The “n”
represents the number of the ethylenoxy repeating units.
Surfactant solutions were prepared by dissolving 6.85 g of NP5 and 20.57 g of NP9 in
123.23 mL of cyclohexane. In a typical reverse micelle reaction two surfactant solutions are
required. The first solution is place into a 1000 mL three necked round bottom flask under
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magnetic stirring. The surfactant solution is degassed for about 20 minutes with nitrogen (N 2)
utilizing the schlenk line technique. Aqueous metal solutions were prepared by dissolving 0.95 g
of FeCl2.4H2O in 6.85 mL of water and 0.57 g of NiCl2.4H2O in 6.85 mL of water. The other
surfactant solution was stirred vigorously while slowly adding the Ni2+ solution. Once the
solution formed micelles and became clear, it was placed in an addition funnel above the round
bottom flask and degassed in the same manner.
Next the aqueous Fe2+ solution was added to the first surfactant solution and degassed for
5 minutes. The colorless surfactant solution presented in the reaction vessel turned pale green
upon the addition of Fe2+ solution. At this point the reverse micelles start to form around the
aqueous Fe2+ solution. Then 0.36 g of NaBH4 was added to the flask and allowed to react for
20 minutes, at the end of which the micelle solution in the addition funnel containing the Ni2+
was added to the reaction for 5 minutes. The addition of second surfactant containing Ni2+ aids
in the formation of the FeOx shell and passivation of the nanoparticles against further oxidation.
The reaction was quenched by the addition of 100 mL of chloroform and 100 mL of methanol
and subsequently washed with methanol to remove excess surfactant and cyclohexane, and then,
the resultant particles were collected in methanol by magnetic separation. After washing was
complete the remaining methanol was decanted and the particles were dried in a vacuum
desiccator. As shown in the Figure 5-9, the as synthesized Fe@FeOx core shell nanoparticles
were dispersed in 0.50 M sodium hydroxide (NaOH) solution and then treated with equivalent
grams of sorbitol and were sonicated for 4 hours. The Fe@FeOx nanoparticles were first coated
with sorbitol to provide a negatively charged particle surface for the Ru(bpy) dye adhere to the
particle surface. The sorbitol treated nanoparticles were then magnetically separated and 50.00
mg of Ru(bpy) dye in 2 mL of water was added.

The nanoparticle dye mixture was further
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sonicated for 4 hours and freeze dried to obtain the nanoparticle dye mixture. The next step is
the encapsulation of this nanoparticle dye mixture by PLGA polymer. The encapsulation was
achieved by emulsification solvent evaporation technique as discussed in chapter 1.

Figure 5-9: Schematic representation of the Fe@FeOx nanoparticle and Ru(bpy) dye
mixture

5.4.3. Overview of Emulsification solvent evaporation technique
The encapsulation of the Fe@FeOx nanoparticles and Ru(bpy) dye by PLGA polymer
was achieved by emulsification solvent evaporation technique.
dispersing two immiscible liquids.

Emulsification is a process of

For emulsion solvent evaporation there are basically two

systems to choose: oil-in-water (o/w) and water-in-oil (w/o). The o/w systems are widely used
compared to w/o systems due to the simplicity of the process and easy clean up requirements for
obtaining the final polymeric particles. In this process the active agents should be hydrophobic
and a water immiscible solvent should be used. In this research work the oil-in-water emulsion
solvent evaporation technique was used to obtain PLGA composites containing Fe@FeOx
nanoparticles and the Ru(bpy) dye. Dichloromethane (DCM) is the most commonly used water
immiscible solvent for preparation of PLGA particles.
The oil-in-water emulsification solvent evaporation technique consists of four major
steps. First step is the dissolution of the active agent in an organic solvent (dichloromethane)
containing the polymer. Second step is the emulsification of this organic phase, called dispersed
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phase, in an aqueous phase called continuous phase followed by extraction of the solvent from
the dispersed phase by the continuous phase, accompanied by solvent evaporation, transforming
droplets of dispersed phase into solid particles. The final step is the recovery and drying of
composites to eliminate the residual solvent.
5.4.4. Preparation of PLGA composites containing Fe@FeOx nanoparticle and Ru(bpy)
dye mixture
Figure 5-10 shows the schematic representation of the o/w emulsion solvent evaporation
technique used to prepare the PLGA composites.

The polymer solution was formed by

dissolving 2 wt% of PLGA in dichloromethane (DCM). The organic phase was formed by
combining 50.00 mg of the nanoparticle-dye mixture and 3 mL of PLGA solution. This organic
phase was sonicated for 5 minutes to achieve uniform dispersion. This organic phase was then
added to 50 mL of aqueous phase containing 3% w/v poly(vinyl alcohol) (PVA) as the stabilizer,
to form the oil-in-water emulsion. PVA helps to reduce the surface tension of continuous phase,
avoids the coalescence and agglomeration of the emulsion droplets formed and stabilizes the
emulsion. The emulsion was homogenized with Ultra Turrax IKA T-18 basic homogenizer at
22,000 rpm for 5 minutes. After that 100 mL distilled water was added to the oil-in-water
emulsion, which dilutes the organic solvent concentration in water and leads to the hardening of
the composites. The solution was stirred overnight to evaporate the organic solvent (DCM) and
then freeze dried. The loading efficiency of the iron core nanoparticles and the thickness of the
PLGA coating can be controlled by varying the ratios of PLGA, iron nanoparticles, and the
fluorescent dye. All characterization and evaluation studies described below were done utilizing
the freeze dried PLGA composites.
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Figure 5-10: Schematic representation of oil-in-water (o/w) emulsion solvent evaporation
technique utilized for the encapsulation of the Fe@FeOx nanoparticles and Ru(bpy) dye
into PLGA polymer

The size distribution and the morphology of the prepared PLGA composites were
determined using a scanning electron microscope (SEM) with a Zeiss EVO 50 (Carl Zeiss, Inc.).
The core-shell morphology and size of the nanoparticles were determined by transmission
electron microscope (TEM) with a Joel JEM-1230 (Joel Ltd.).

The loading efficiency of the

iron nanoparticles and the dye, and the release rate of the dye were determined by fluorescence
spectroscopy and thermogravimetric analysis (TGA)
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5.5. Results and discussion
The size and morphology of the as synthesized Fe@FeOx core shell nanoparticles was
confirmed by transmission electron microscopy (TEM). The TEM sample was prepared by redispersing the Fe@FeOx nanoparticles in methanol, and then applied to a 300 mesh copper TEM
grid with a carbon film.

Figure 5-11 shows the TEM image of the Fe@FeOx core shell

nanoparticles. A well-defined core shell nanostructures with a size distribution in the range of 10
to 15 nm is observed. The inner dark centers represent the metallic iron core and the outer light
color rings represent the iron oxide shell. These results confirm the core shell morphology of the
synthesized Fe@FeOx nanoparticles.

20nm

Figure 5-11: Transmission electron microscopy (TEM) image of Fe@FeOx core shell
nanoparticles synthesized by reverse micelle technique.
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Scanning electron microscopy (SEM) was performed to determine the size distribution
and the morphology of the prepared polymeric composites. The freeze dried PLGA composites
were re-suspended in water with sonication, mounted onto a carbon conductive tab (Ted Pella,
Inc., Redding, CA, USA), and dried at room temperature overnight. The sample was sputter
coated with gold plasma prior to SEM imaging.

Figure 5-12 shows the SEM image of the

magnetic PLGA composites, which are roughly around 200 nm–1.5 μm in size and show fairly
spherical structure. The size distribution of the composites is attributed to the oil-in-water
droplet formation and the solvent evaporation from the polymer solvent interface. In general,
longer homogenization times and higher speed of the homogenizer produces higher shear
induced by the homogenizer blade, thus, leading to smaller particle size. Too much loading of
the Ru(bpy) dye and the nanoparticles leads to the loss of morphological control and the
composites turn into irregular shapes as seen in the Figure 5-12. The most likely explanation to
this would be that the Ru(bpy) dye could precipitate in due to lack of water during the Fe@FeOx
nanoparticle-Ru(bpy) dye mixture formation. The particle size of the precipitated dye could be
bigger than the oil-in-water bubbles formed. Thus disturbing the droplet formation and leading
to smear formation. The other speculation is that as the dye content is increased in the organic
phase, more dye is likely to get solubilize into the aqueous phase as Ru(bpy) is a water soluble
dye. This leads to the disturbance in the formation of the droplet.
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Figure 5-12: Scanning electron microscopy (SEM) image of the magnetic PLGA composites
The loading efficiency of the prepared magnetic PLGA composites was determined using
Thermogravimetric analysis (TGA) and fluorescence spectroscopy.

5 mg of the PLGA

composite were dissolved in DCM; PLGA is soluble in DCM while the Fe@FeOx nanoparticles
and the Ru(bpy) dye fall out in the organic solution. To this DCM solution a known volume of
water was added to extract the water soluble Ru(bpy) dye. Fluorescence measurements were
performed on the aqueous layer to determine the Ru(bpy) dye content in 5 mg of the composites.
Fluorescence intensity of known concentration of Ru(bpy) dye was measured and a linear curve
fit was performed which yields around 0.25% w/w fluorescent Ru(bpy) dye loading in the
composites as shown in Figure 5-13. Attempts were made to improve the loading efficiency of
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the dye but it leads to the loss of the spherical morphology of the composites, as discussed
earlier.

Figure 5-13: Linear regression plot yielding a 0.25% w/w Ru(bpy) loading into the PLGA
composites
TGA results also confirmed 0.25% w/w Ru(bpy) dye loading and shows approximately
50% w/w Fe@FeOx nanoparticles loading in the composite as shown in Figure 5-14. The
decomposition of PLGA polymer by itself occurs at around 200 ºC, but the PLGA composites
start to degrade at around 160 ºC. The PLGA polymer is in a form of amorphous bead but when
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the PLGA composites are formed the polymer was dissolved in DCM and re-precipitated out.
This causes an increase in the atacticity of the polymer. Two decomposition events around 380
ºC and 450 ºC are observed for Ru(bpy) corresponding to the decomposition of the bipyridyl
rings. The PLGA composites shows a small decomposition event around 400 ºC corresponding
to Ru(bpy) dye indicating a trivial amount of the dye. The Ru(bpy) dye loading obtained is very
less and can be attributed to the loss of the water soluble Ru(bpy) dye during the emulsification
process.

The Fe@FeOx nanoparticles do not undergo any decomposition till 600 ºC thus

yielding a loading of around 50% in the composite.

Figure 5-14: TGA plot showing the decomposition profile of PLGA composites containing
Fe@FeOx nanoparticles and Ru(bpy) dye, PLGA and Ru(bpy) dye by itself
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5.6. Ru(bpy) dye release studies
Fluorescence spectroscopy was performed to study the release kinetics of the Ru(bpy)
dye from the PLGA composites. Ru(bpy) dye is a fluorescent dye with excitation wavelength of
470 nm and emission wavelength around 610 nm. Therefore, the PLGA composites were
excited at 470 nm using Cary Eclipse Fluorescence Spectrophotometer equipped with a xenon
lamp. As the dye is released from the composite, the fluorescence intensity decreases due to the
quenching of the Ru(bpy) dye by the Fe@FeOx nanoparticles as discussed earlier, thus allowing
for the determination of the release kinetics of the dye as a function of temperature. The PLGA
composites were dispersed in water and heated with 2.45 GHz microwave radiations by
irradiating with a pulse of 1 second duration each utilizing a commercial microwave unit. The
microwave radiations heats up the magnetic nanoparticles by magnetic hyperthermia principle as
discussed.

Figure 5-15: Physical mechanism at each frequency range of electromagnetic spectrum
range
Electromagnetic (EM) radiation can be classified into ionizing radiation and non-ionizing
radiation, based on whether it is capable of ionizing atoms and breaking chemical bonds as
shown in the Figure 5-15. Non-ionizing EM radiations propagate within biological tissues with
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reduced velocities, and are refracted, diffracted and reflected when encountering inhomogeneities within tissues.

For heat generation the non-ionizing radiations of the EM

spectrum are widely used by diversified system configurations. Microwave radiations are widely
used EM radiation to generate heat within the body. Microwaves are defined as the region of the
non-ionizing spectrum from 300 MHz to 30 GHz. Microwaves interact with biological systems
by way of ionic conduction and rotation of polar molecules of water. Microwave energy is
generated by a magnetron, and transmitted either directly or by means of a waveguide. The
Federal Communications Commissions for industrial, scientific, and medical applications has
allotted the 0.955 and 2.450 GHz frequency bands for hyperthermia applications. 182

In the

0.915 GHz band, resistive heating is achieved by collision of the freely moving ions within the
body while at the 2.45 GHz frequency bands heat is generated but to the dielectric heating of
water and fats within the body. Due to this microwave energy leads to overheating of the fatty
tissues. Despite these problematic overheating, microwaves are still among the mainstream
hyperthermia applications due to several appealing experimental and clinical results. Also the
overheating can be controlled by maintaining the exposure time of the microwave radiations as
defined by the International Commission on Non-Ionizing Radiation Protection (ICNRP)183,184
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Figure 5-16: Plot of fluorescence intensity vs time. The horizontal lines shows the
fluorescent intensity at room temperature 22 °C, 30, 40, and 50 °C temperature as
measured by fluorescence spectrometer.
The magnetic nanoparticles when irradiated with the microwave radiations produce heat
by magnetic hyperthermia principle as discussed earlier. The 2.45 GHz frequency with 1 second
pulse was used for the in-vitro experiments and past studies have shown that few seconds’
exposure to the microwave radiations does not have any major effect on the healthy tissue. 185,186
To achieve uniform heating of the composite sample and water as the reference, the turntable
within the microwave unit was removed and the composite sample and water were heated from
one to five times with a pulse of 1 second duration each. The iron nanoparticles encapsulated
within the composite absorb the microwaves and heats up providing local heating. The PLGA
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polymer swells up due to the heat produced leading to the release of the dye through the erosion
of the polymer. The bulk water temperature of the composite sample as well as the reference
reached up to 32 °C after irradiating the sample five times with a pulse of 1 second duration
each. Fluorescent measurements were carried out after irradiating the sample for one to five
times with 1 second pulse each, as well as heating the sample to 30, 40, and 50 °C. The sample
was just heated five times as further heating leads to drastic increase in the temperature of the
sample. Figure 5-16 shows the plot of the fluorescence intensity with time of irradiation of the
sample by the microwaves and externally heating the sample at 30, 40, and 50 °C. It can be seen
that the rate of release of the dye at 2 seconds is equal to that of 30 °C and the 4 seconds
irradiation release equals to 40 °C.

5.7. Conclusion
Successful encapsulate the drug analog Ru(bpy) dye and magnetic Fe@FeOx
nanoparticles into the PLGA composites was achieved by oil-in-water emulsion solvent
evaporation technique.

The local heating of the PLGA composites was also achieved by

irradiating the Fe@FeOx nanoparticles with 2.45 GHz microwave radiations. The release of the
Ru(bpy) dye from the PLGA composites after microwave irradiation was successfully achieved.
Also higher Ru(bpy) dye release from the composites by locally heating the sample with 2.45
GHz microwave pulse compared to externally heating the composite sample was demonstrated.
Fe2+and Fe3+ ions acts as a very good quencher for the fluorescent Ru(bpy) dye, which is
observed with the decrease in the fluorescence intensity of the released dye at 610 nm when the
temperature is increased externally or by irradiating the sample five times with 1 second pulse
each from a 2.45 GHz commercial microwave unit. The composite sample when irradiated with
microwaves or externally heated at 30, 40 or 50 ˚C, the sorbitol layer on the nanoparticles
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decomposes at that temperature. The sorbitol was used to provide a barrier between the iron
oxide nanoparticles and the Ru(bpy) dye so that they do not come in contact with each other
leading to dynamic quenching of the Ru(bpy) dye. The quenching of the Ru(bpy) dye by the
iron oxide nanoparticles is observed when the composites are irradiated or heated externally. As
a result a systematic study of the quenching process of the ruthenium dye needs to be done. To
clearly understand the quenching process of the Ru(bpy) dye in-situ measurements of the dye
release need to be done. For this reasons Radio frequency (Rf) radiations were used instead of
2.45 GHz microwave radiations to generate heat from the magnetic iron nanoparticles by
magnetic hyperthermia principles. It is easier to mount an Rf frequency coil on the sample
carrying out simultaneous heating and fluorescent measurements. Also a bench top fluorescence
spectrometer equipped with 530 nm laser source was used to carry out in-situ measurements. An
Rf frequency coil was mounted on the sample and then fluorescence measurements are carried
out.

A detailed explanation of the experimental set up and the results obtained will be given in

chapter 6.

Chapter 6. Ferrofluid based drug delivery system with dual modal imaging
and therapeutic applications
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6.1. Overview
As discussed earlier a drug delivery system made up of biodegradable and biocompatible
PLGA polymeric composites containing the Fe@FeOx nanoparticles and the drug analog has
been successfully designed.

But as seen in the previous results the PLGA composites

synthesized were poly-dispersed with a wide size distribution of around 200 nm–1.5 μm. For invitro applications mono-dispersed PLGA composites with higher dye loading efficiency are
desirable. To obtain mono-dispersed PLGA composites, the magnetic Fe@FeOx nanoparticles
need to be dispersed in either organic or aqueous medium.

The PLGA composites earlier

synthesized in chapter 5 were prepared by oil-in-water (o/w) emulsion technique. The basic
principle of this technique is that both polymer and the active agents to be encapsulated need to
be dispersed/ dissolved into the organic phase (DCM), and the resultant organic phase is
emulsified into the water phase containing the emulsifier of choice. In the earlier case when
Fe@FeOx nanoparticle-Ru(bpy) dye mixture was encapsulated into the PLGA polymer, the
nanoparticle-dye mixture did not form a stable disperse into DCM. So it was a solid-in-oil-inwater (s/o/w) emulsion, in which a solid is dispersed into the organic phase which is then
emulsified in the aqueous phase.187 But the s/o/w technique has certain drawbacks such as
formation of poly-dispersed composites and increase in the burst release of the active agent. In
s/o/w technique very low and uniform particle size of the active agent is required for the
complete encapsulation.188

Therefore the poly-dispersed in the PLGA composites could have

come from the poly-dispersed Fe@FeOx nanoparticle-Ru(bpy) dye mixture. To overcome this
problem the nanoparticle-dye mixture needs to be dispersed into the organic phase. The Ru(bpy)
dye is soluble in the aqueous as well as organic phase but the Fe@FeOx nanoparticles do not
disperse into organic as well as the aqueous phase. So, it is essential to obtain a stable dispersion
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of the magnetic nanoparticles into the desired solvent. This can be achieved by using a ferrofluid
instead of the iron nanoparticles.
This chapter first describes the synthesis of the chloroform based ferrofluid by
thermolysis technique followed by its characterization. The next step is the preparation of the
PLGA composites utilizing the synthesized ferrofluid and the drug analog by oil-in-water
emulsion solvent evaporation technique. The PLGA composites were further functionalized with
folic acid for targeted delivery. The functionalization of the PLGA was achieved utilizing
carbodiimide chemistry and will be discussed in detail in section 6.4. The release of the drug
analog from the functionalized PLGA composites was studied by fluorescence spectroscopy
while placing the sample in a radio frequency (Rf) induction coil. The PLGA composites were
also investigated by magnetic resonance relaxivity measurements for its application in MRI

6.2. Ferrofluid
Ferrofluids are stable colloidal suspensions of nanoscale magnetic particles into a carrier
fluid, usually organic solvent or water. 148,189

The magnetic nanoparticles have an average

particle size of about 10 nm that are suspended by Brownian motion and do not settle out, even
when exposed to a strong magnetic, or gravitational field.

The magnetic nanoparticles are

mainly nanoscale magnetite or maghemite. In the absence of a magnetic field, the magnetic
moments of the nanoparticles are randomly distributed and the ferrofluid has no net
magnetization. But when a magnetic field is applied to a ferrofluid, the magnetic moments of the
nanoparticles orient along the field lines almost instantly. The magnetization of the ferrofluid
responds immediately to the changes in the applied magnetic field and when the applied field is
removed, the moments randomize quickly.
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The magnetic nanoparticles of the ferrofluid are coated with a stabilizing dispersing
agent that prevents the particle agglomeration even when a strong magnetic field is applied to the
ferrofluid. These stabilizers prevent the nanoparticles from clumping together, ensuring that the
particles do not form aggregates that become too heavy to be held in suspension by Brownian
motion. There are two main types of stabilizers used for dispersing magnetic nanoparticles such
as

the

surfactant

stabilized

nanoparticles

and

ionically

stabilized

nanoparticles.

Tetramethylammonium hydroxide is the most commonly used ionic stabilizer for polar solvents
based ferrofluid. The positively charged tetramethylammonium hydroxide [N(CH 3)4+] cation
forms a diffuse shell around the negatively charged nanoparticle surface, inducing electrostatic
repulsion between the neighboring particles. For non-polar solvents based ferrofluid, surfactants
are used to coat the nanoparticle surface that induces steric repulsion on the neighboring
nanoparticles. The most commonly used surfactants are oleic acid, citric acid, and soy lecithin.
A surfactant has a polar head which adsorbs to a nanoparticle and non-polar tail that sticks out
into the carrier medium preventing the agglomeration of the nanoparticles. The stability of the
ferrofluid is influenced by several parameters such as an optimum size range of the
nanoparticles, viscosity of the carrier liquid, length of the surfactant, temperature, and magnetic
field strength. Various techniques have been shown to produce magnetic nanoparticles such as
wet grinding, co-precipitation, micro-emulsion, and thermal decomposition of metal salts
(thermolysis).189-191

After the synthesis of the nanoparticles, additional steps are typically

required to coat them with the appropriate stabilizer.
6.2.1. Synthesis
Thermolysis is a synthetic technique where in the nanoparticles are synthesized by
thermally decomposing the metal precursor in high boiling organic solvents containing
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stabilizing surfactant.192,193 Mono-dispersed nanoparticles can be achieved through thermolysis
technique. Furthermore, utilizing this technique the surfactant coating of the nanoparticle can be
achieved in a single step process.

Figure 6-1: Synthetic scheme for the design of the chloroform based ferrofluid

Figure 6-2: Schematic representation of the magnetic nanoparticles coated with sodium
oleate in the ferrofluid. The sodium oleate chains induces steric repulsion on the
neighboring particles preventing the agglomeration
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Chloroform based ferrofluid was synthesized by thermolysis technique under ambient
conditions. 1.00 g of iron (II) chloride tetrahydrate (FeCl2.4H2O) and 2.50 g of sodium oleate
are placed in a 100 mL one neck round bottom flask. Sodium oleate is used here as a surfactant
to coat the magnetic nanoparticles as shown in Figure 6-2. The sodium oleate induces steric
repulsion between the neighboring nanoparticles thus preventing agglomeration. Then 25 mL of
n-butanol is slowly added to the flask under magnetic stirring. The reaction solution is quickly
heated to reflux conditions for an hour. During which the reaction solution undergoes a color
change from dark orange to grey and finally to jet black at the end of 1 hour reflux.

After an

hour the reaction solution was allowed to cool to room temperature and quenched with the
addition of 100 mL methanol. Throughout the reaction the particles did not seem to stick to the
magnetic stirrer during the reaction. The nanoparticles are magnetically extracted and further
washed several times with methanol. The methanol washing step is necessary to remove any
excess of the sodium oleate surfactant.

To prepare the chloroform based ferrofluid, the

nanoparticles were taken in a vial and chloroform was slowly added under sonication. The
colloidal stability of the prepared ferrofluid was checked with a rare earth magnet. The resulting
ferrofluid is stable for over six months without visual degradation.
The next step is the preparation of the PLGA composites utilizing the ferrofluid and the
drug analog. In previous work Ru(bpy) dye was used as the drug analog, but the loading
efficiency was too low around 0.25%. Another dye Rose Bengal was used but it also suffered
from the same problem of poor loading. Both Ru(bpy) and Rose bengal are water soluble and
leached out during the emulsification process leading to poor encapsulation efficiency.
Moreover most of the anticancer drugs are water insoluble so we need a water insoluble drug
analog. Rhodamine B base is a sparingly soluble in water.

Rhodamine B base is a fluorescent
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dye belonging to the family of fluorone dyes and its structure is as shown in Figure 6-3.
Rhodamine B base has and excitation wavelength around 540 ± 2 nm and emission wavelength
around 580 ±2 nm. Rhodamine B base also undergoes dynamic quenching by Fe2+and Fe3+ ions
through excited state charge transfer mechanism. 176,194

Figure 6-3: Chemical structure of Rhodamine B base dye

6.3. Preparation of the PLGA composites containing the Ferrofluid and Rhodamine
B dye
The PLGA composites containing the ferrofluid and Rhodamine B base dye were
synthesized by oil-in-water emulsion solvent evaporation technique as discussed earlier with a
slight modification. In the previous work the first step was the preparation of the nanoparticledye mixture. But it is know that the metal ions quench the dye through excited state charge
transfer mechanism. The efficiency of the quenching depends on the distance between the donor
and the acceptor species.177 So, if the distance between the donor and acceptor species is
increased the quenching process can be restricted.
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Figure 6-4: Schematic representation of modified oil-in-water (o/w) emulsion solvent
evaporation technique utilized for the encapsulation of the ferrofluid and Rhodamine B
base dye into PLGA polymer
Figure 6-4 represents the schematic representation of the synthetic scheme for preparing
the PLGA composites. Firstly the polymer solution was formed by dissolving 200.00 mg of
PLGA in 3 mL of dichloromethane (DCM). This polymer solution was divided into half. To the
first half 1 mL of chloroform based ferrofluid was added while 20.00 mg of the Rhodamine B
dye was added to the other half polymer solution. Both the ferrofluid and the dye containing
solutions were sonicated for 5 minutes to achieve uniform mixing. The two polymer solutions
were then mixed together to form the organic phase. This organic phase was then added to 50
mL of aqueous phase containing 2% w/v poly(vinyl alcohol) (PVA) as the stabilizer, to form the
oil-in-water emulsion. PVA helps to reduce the surface tension of continuous phase (aqueous
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phase), avoids the coalescence and agglomeration of the emulsion droplets formed and stabilizes
the emulsion. The emulsion was homogenized with Ultra Turrax IKA T-18 basic homogenizer
at 60,000 rpm for 1 minute. After that 50 mL of 0.25% w/v PVA solution was added to the oilin-water emulsion and further homogenized at 40,000 rpm for another minute. This dilutes the
organic solvent concentration in water and leads to the hardening of the composites. The
solution was stirred for 4 hours to evaporate the organic solvent and then freeze dried. PLGA
composites containing just the dye as well as the ferrofluid were also synthesized by the same
procedure as controls. The prepared PLGA composites were stored in vial till further use.

6.4. Functionalization of the PLGA composites with Folic acid
For an effective drug delivery active targeting of the active agent to the tumor site is
necessary. As discussed in chapter 1, Folic acid (FA) is a water soluble vitamin that can be used
for tumor targeting via folate receptor mediated endocytosis.

Folate receptor has been known

to be greatly over expressed in several human tumors such as ovary, lung, breast, kidney, and
brain. Folic acid has emerged as an attractive ligand for drug targeting due to its low molecular
weight (MW-441), which allows for good tissue penetration. Also FA can be easily attached to
the PLGA composites through carbodiimide chemistry.

The PLGA composites can be

functionalized with FA prior to the composite formation or can be conjugate to the pre formed
PLGA composites. The FA conjugation prior to the composite formation is preferred as it is
found to be robust as compared to the functionalization of the pre formed composite.
The functionalization of PLGA by FA was carried out in three steps. The first step was
modification of the PLGA surface by controlled aminolysis to produce primary and secondary
amine groups on the surface. The second step was activation of the FA by EDC and NHS. And
the final step was the conjugation of the activated FA with aminolyzed PLGA.
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6.4.1. Controlled aminolysis of PLGA

Figure 6-5: Controlled aminolysis of the PLGA polymer with ethylenediamine
Aminolysis is a technique that is used for surface modification of polyesters. 195-197 The
reaction proceeds via nucleophilic attack on the carbonyl carbon to form a positively charged
tetrahedral intermediate. Under basic conditions, the tetrahedral intermediate is deprotonated
and the reaction proceeds to the formation of an amide and an alcohol as shown in Figure 6-5.
200.00 mg of premade PLGA were immersed in aqueous solution of 5 mL of 0.05 M
ethylenediamine (ED) for 15 minutes. The aminolyzed PLGA was then washed three times with
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ice cold water to remove any excess of ethylenediamine. IR spectroscopy was performed on the
aminolyzed PLGA to confirm the presence of the amino groups.
6.4.2. Activation of Folic acid (FA)
The chemical conjugation of aminolyzed PLGA with folic acid (FA) was carried out
utilizing the carbodiimide chemistry. Carbodiimide is a functional group containing the general
formula RN=C=NR. In synthetic chemistry carbodiimides are used to form amide linkage
between carboxylic acids and amines.

Dicyclohexylcarbodiimide (DCC) is a zero length

crosslinking agent used to couple carboxyl groups to primary amines. DCC reacts with a
carboxyl group forming an amine-reactive O-acylisourea intermediate. This intermediate may
react with an amine, yielding an amide. However, the failure to react quickly with an amine
results in hydrolysis and regeneration of the carboxyl moiety.

The addition of N-

hydroxysuccinimide (NHS) stabilizes the amine-reactive intermediate by converting it to an
amine-reactive NHS ester, thus increasing the efficiency of DCC-mediated coupling reactions.
The amine-reactive NHS ester intermediate has sufficient stability to permit two-step
crosslinking procedures.
The carboxylic group of folic acid was activated by DCC and NHS as shown in the
synthetic scheming in Figure 6-6.

Briefly, 1.00 g of FA was dissolved in 20 mL of

dimethylsulfoxide (DMSO) in a 100 mL one neck round bottom flask under magnetic stirring.
Then 1.10 g of NHS and 1.10 g of DCC were added to the FA solution (folic acid/NHS/DCC
molar ratio=1:1.1:1.1). The reaction mixture was allowed to react at room temperature for 12
hours in dark. At the end of 12 hours of reaction, white byproduct N,N'-dicyclohexylurea
precipitates are found. The reaction mixture is filtered through glass wool plug and precipitated
with ethyl ether.

The precipitated FA-NHS ester was pelleted by centrifugation and the
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supernatant was removed. The precipitated FA-NHS ester was vacuum-dried and stored in an
amber vial till further use.

Figure 6-6: Activation of the carboxyl group of FA with DCC and NHS to form the FANHS ester
6.4.3. Conjugation of FA-NHS ester with aminolyzed PLGA
200.00 mg of aminolyzed PLGA was dissolved in 10 mL DCM in a 25 mL round bottom
flask under magnetic stirring. Then 200.00 mg of FA-NHS ester was added to it and was let to
react for 4 hours. After the end of 4 hours the FA functionalized PLGA (FA-PLGA) was
precipitated with ethyl ether. The precipitated FA-PLGA was pelleted by centrifugation and the
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supernatant removed. The pellet was re-dissolved in DCM (<1 mL), precipitated, and centrifuged
once more to remove any unreacted FA-NHS ester.
This FA -PLGA polymer was used to synthesis the composites utilizing the ferrofluid and
Rhodamine B dye by modified oil-in-water emulsion solvent evaporation technique as discussed
in section 6.3.

6.5. Results and Discussion
The ferrofluid and PLGA composites were characterized by x-ray diffraction, electron
microscopy, vibrating sample magnetometry, and fluorescence spectroscopy to determine the
phase, size and morphology, saturation magnetization and the loading percentages of the dye and
nanoparticles. The chloroform based ferrofluid was evaporated in a watch glass to obtain dried
nanoparticles powder. These dried nanoparticles were used for the powder XRD and VSM
measurements.
Powder x-ray diffraction (XRD) measurements were performed using a Panalytical
X’pert pro diffractometer at a scanning step of 0.05º with a 2θ range from 20º to 80º using a
graphite monochromated Cu-Kα radiation source. Sample was ground and pressed onto a no
background, low volume silicon holder. Figure 6-7 shows the powder XRD pattern of the as
synthesized ferrofluid nanoparticles with an overlay of the data obtained from the JSPDS
reference powder diffraction pattern of magnetite. 198 The pattern shows a pure phase magnetite
(Fe3O4). Major diffraction peaks for magnetite at 30.125°, 35.483°, 37.117°, 43.124°, 53.501°,
57.033°, 62.949°, 71.430°, 74.493°, 75.504°, and 79.504° correspond to the (220), (311), (222),
(400), (422), (511), (440), (620), (533), (622), and (444) miller indices, respectively. The peaks
were indexed by the JCPDS database for magnetite (fd3m, card#01-086-1343).
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Figure 6-7: Powder x-ray diffraction pattern of as synthesized ferrofluid

The size and morphology of the synthesized ferrofluid was confirmed by transmission
electron microscopy (TEM). Figure 6-8 shows relatively uniformed size spherical nanoparticles
with average diameter of 10±5 nm. The spherical nanoparticles seem to be agglomerated and not
mono-dispersed in the TEM image.

The agglomeration can rise from the TEM sample

preparation. For the TEM grid preparation the dried magnetite nanoparticles were dispersed in
methanol and then around 5 μL of the dispersed solution was placed on the copper grid. We
believe that the agglomeration of the particles is induced by drying of the ferrofluid
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Figure 6-8: TEM image of the magnetite nanoparticles in the ferrofluid.
The FA functionalization of the PLGA composites was confirmed by both FTIR and UVVis. spectroscopy. The appearance of the amide linkage in the FTIR confirms the covalent
attachment of the FA to PLGA. The presence of the characteristic bands of FA in the FA
conjugated PLGA also confirms the covalent attachment of FA.
Figure 6-9 shows the IR spectra of PLGA, aminolyzed PLGA, FA functionalized PLGA
and FA by itself. From the spectrum of PLGA, it can be observed that there is a strong
characteristic band at 1740 cm-1 corresponding to the stretching vibrations of the carbonyl group
(C=O), the bands at 2940 and 2990 cm-1 are assigned to the C–H stretching vibrations of the –
CH2 groups in the backbone chains of PLGA. Similarly, the bands at 1160 and 1070 cm-1 are
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attributed to C–O stretching of the ester group. When aminolyzed PLGA was analyzed by IR,
similar peaks to those of PLGA were observed with additional bands appearing at 1640 and 1570
cm-1 due to N-H bending vibrations of amine group (NH2). The presence of this band confirms
the presence of amine groups on the PLGA. The folic acid functionalized PLGA (FA_PLGA)
shows characteristic bands of PLGA as well as folic acid. The band at 3550 and 3300 cm -1
corresponding to O-H and N-H stretching vibrations of amide group, 1610 cm-1 corresponds to
the C=O stretching vibrations of amide group and 1380 cm-1 corresponding to C-N stretch for
amide group. The appearance of the characteristic bands of amide group confirms the covalent
attachment of folic acid with PLGA While the IR spectrum of folic acid is characterized by
bands between 3600 and 3000 cm-1 are due to the OH stretching and N-H stretching vibration
bands, band at 1670 cm-1 for C=O stretching vibrations from carboxyl group (COOH) and 1600
cm -1 for N-H bending vibrations of amine group (NH2).177
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Figure 6-9: IR spectra of PLGA, aminolyzed PLGA (PLGA-NH2), FA functionalized
PLGA and FA
Further the FA functionalization of PLGA was confirmed by UV-vis spectroscopy.
Figure 6-10 shows the absorbance spectra of the FA functionalized PLGA polymer (FA-PLGA)
and folic acid by itself. The FA absorbs UV light and has absorption peaks at 210, 280 and 360
nm.199,200

The absorbance spectra of the FA functionalized PLGA also shows absorbance

maxima at 280 and 360 nm confirming the covalent attachment of the folate. The FA and FAPLGA samples for absorbance measurements were prepared by dispersing about 1 mg each in
water. The absorbance of the aqueous suspension was measured in a quartz cuvette.
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Figure 6-10: UV-Vis absorbance spectra of the FA functionalized PLGA polymer. Inset
shows the absorbance spectra of pure folic acid (FA)
Scanning electron microscopy was performed on Hitachi SU-70 field emission scanning
electron microscope to evaluate the size distribution and morphology of the magnetic PLGA
composites and the FA-PLGA composites containing the dye and the ferrofluid. Both PLGA
and FA-PLGA composites samples were prepared by lightly sprinkling the composite powder on
a conductive carbon tape mounted on the sample holder.

The sample was then sputtered with

gold to make it conductive and reduce charging. As seen in Figure 6-11 the PLGA composites
are relatively uniform sized with an average diameter of 300±50 nm while the FA-PLGA
composites are found to be spherical with a wider size distribution. The FA-PLGA composite
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looks as if they are interconnected and we speculate that it occurs due to excessive charging of
the FA-PLGA composites even after sputtering it with conductive gold.

Figure 6-11: SEM image of the PLGA composites utilizing the ferrofluid and Rhodamine B
dye. (A) PLGA composites, (B) FA-PLGA composites
The loading efficiency of the prepared PLGA composites was determined by
fluorescence spectroscopy. Rhodamine is acetone soluble so 4.00 mg of the PLGA composite
were dissolved in 10 mL of acetone and filtered to remove the iron oxide nanoparticles.
Fluorescence measurements were performed on the filtrate to determine the dye content in 4 mg
of the composites. Fluorescence intensity of known concentrations of dye was measured and a
linear curve fit was performed which yields around 1.97% w/w dye loading in the PLGA
composites containing both dye and ferrofluid.
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Figure 6-12: Linear regression plot yielding a 1.97 % w/w Rhodamine B dye loading into
the PLGA composites
Thermogravimetric analysis (TGA) was performed on the PLGA composites containing
the dye and ferrofluid (magnetic PLGA comp.), as well as the controls- PLGA dye composite,
PLGA ferrofluid composite and PLGA by itself. As can be seen in Figure 6-13 TGA plot yields
around 2 % w/w Rhodamine B dye and 6.67 % w/w magnetite nanoparticle loading. The
decomposition event around 240º C attributed to the decomposition of PLGA as seen in figure.
The decomposition event around 240º C is observed in the magnetic PLGA composites
decomposition profile. The Rhodamine B dye yields two decomposition events around 315 º C
and 430 º C. A trivial decomposition event is observed at 315º C and 430º C attributed to the
decomposition of Rhodamine B dye in the magnetic PLGA composites decomposition profile.
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The ferrofluid shows a decomposition event around 200º C due to the decomposition of the
sodium oleate surfactant on the surface of the particles. The magnetite nanoparticles thereafter
are stable and show no degradation till 600º C.

Figure 6-13: TGA plot showing the decomposition profile of the PLGA composites and the
controls
Magnetic characterization was performed on the chloroform based ferrofluid as well as
the PLGA composites by room temperature vibrating sample magnetometer (VSM) after drying
the fluid. Figure 6-14 shows a hysteresis plot of the as synthesized ferrofluid and PLGA
composites. The saturation magnetization of the iron oxide nanoparticles was around 105 emu/g.
As seen in the inset the corecivity of magnetite nanoparticles is found to be negligible. The
saturation magnetization of the bulk magnetite is found to be around 90-120 emu/g.

The
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decrease in the magnetization of the magnetite nanoparticles is attributed to the surfactant
coating on the surface of the particles.

The inset shows the hysteresis plot of the PLGA

composites containing the dye and the ferrofluid yields net magnetization around 8.18 emu/g.
Utilizing the TGA data for weight correction the net magnetization of PLGA composites was
found to be 100.00 emu/g. The hysterysis loop for the PLGA composites is observed to be very
noisy because the volume of magnetite nanoparticles is very less within the PLGA composites as
well as the particles is randomly spread within the composites.

Figure 6-14: Room temperature VSM data of the as-prepared ferrofluid material plotted as
magnetization (emu/g) versus applied field (Oe)
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Fluorescence spectroscopy was employed to study the release kinetics of the Rhodamine
B dye from the PLGA composite while placing the sample in a radio frequency (Rf) induction
heating coil. Fluorescence measurements were performed on an open bench top HORIBA Jobin
Yvon spectrometer equipped with a 535 nm laser source and synapse CCD detector shown in the
Figure 6-15.

Figure 6-15: Block diagram of the open bench top fluorescence spectrometer equipped with
laser and the Rf heating coil set

6.5.1.Rf induction heating
Rf induction heating was carried out using Ambrell Inc. Model Easyheat 0224 induction
heating system. In a basic induction heating setup shown in Figure 6-16, a solid state Rf power
supply sends an AC current through an inductor coil (often a copper coil). The passage of
current through this coil generates a very intense and rapidly changing magnetic field in the
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space within the inductor coil and the sample to be heated is placed inside the coil. The intense
alternating magnetic field inside the inductor coil repeatedly magnetizes and de-magnetizes the
iron oxide nanoparticles. This rapid flipping of the magnetic domains causes considerable
friction and heating inside the material. The magnetic hyperthermia induced by Rf radiations is
termed as Rf hyperthermia.

Figure 6-16: Block diagram of the basic induction heating coil system
The Rf hyperthermia technique offers benefits over existing hyperthermia treatments
such as the technique can be localized using suitable Rf coils.201,202 Also Rf can be used for
heating deep-seated tumors compared to microwave hyperthermia that has a poor depth of
penetration, which makes it unsuitable for treatment of deep-seated tumors. The microwave
radiations also heats up the surrounding water molecules by dielectric heating producing
excessive heat.186 Another major benefit of Rf hyperthermia is that it can be integrated into
magnetic resonance imaging (MRI) systems for simultaneous treatment and monitoring. 202
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Figure 6-17: Plot of fluorescence intensity with the time of Rf induction heating of the
PLGA composites. An increase in the fluorescence intensity is observed with time.
The PLGA composites were dispersed in water and sonicated for about 15 minutes to
remove the aggregated particles and then magnetically extracted and re-dispersed in water. Insitu fluorescence measurements were carried out on the dispersed PLGA composites at every 30
seconds time interval for 30 minutes while the sample was placed in the Rf induction coil.
Figure 6-17 shows that the fluorescence intensity of the PLGA composites increases linearly
with time of Rf induction heating.
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Figure 6-18: Plot of fluorescence intensity with the time of pulsed Rf induction heating of
the PLGA composites. An increase in the fluorescence intensity is observed when the Rf
pulse is switched ON and the intensity decreased when the Rf pulse is switched OFF
A pulsed Rf treatment of the PLGA composites was also carried out which showed a
corresponding increase in the rate of the dye release when the PLGA composites were heated (Rf
pulse ON) and the rate of dye release decreases when RF pulse was OFF. As seen in Figure 6-18
the fluorescent intensity increases slightly in the first 10 minutes when the RF pulse is OFF, due
to the burst release of the dye at the surface of the composites. For the next 10 minutes i.e.
between 10 to 20 minutes when the Rf pulse is ON an increase in fluorescent intensity is
observed. An insignificant increase in intensity is observed from 20 to 30 minutes when the Rf
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pulse OFF and that is due to the remnant heat left when the Rf pulse was ON. With the next Rf
pulse ON between 30 to 40 minutes, a significant increase in the intensity is observed and again
the intensity decreases when the Rf pulse is switched OFF between 40-50 minutes.

Figure 6-19: Plot of DLS results showing the increase in size with the increase in
temperature
We speculate that when the magnetite nanoparticles are inductively heated that heat up
the surrounding polymeric composite leading it to swell. The swollen polymeric composites in
turn lead to the release of Rhodamine B dye. The swelling up of the PLGA composites due to
the heat is confirmed by dynamic light scattering measurements. Figure 6-19 shows the plot of
temperature vs. the average particle size of the PLGA composites containing the dye and
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ferrofluid as well as the PLGA composites by itself. An increase in the size of the composites is
observed with increase in the temperature. Similar results were obtained for PLGA controls.

6.6. MRI contrast application
This ferrofluid was also investigated in vitro by magnetic resonance relaxivity
measurements for its application in magnetic resonance imaging.

The magnetic resonance

imaging (MRI)/spectroscopic experiments were performed on a 2.4 T/40 cm bore MR system
(Biospec/Bruker). For magnetic resonance relaxivity measurements the PLGA composites were
dispersed in low melting agarose gels to avoid settling of the composites.
6.6.1. MRI sample preparation
The 1% agarose (w/v) gels were prepared by dissolving agarose powder in deionized
water. The solution was heated in a microwave oven while stirring occasionally to ensure
complete dissolution of agarose. The MRI relaxation times were measured for gels containing
PLGA composites with concentrations of 0.6700, 0.3350, 0.1675, 0.0838, and 0.0419 mM.

A

control sample without PLGA composites was measured.
The MRI/spectroscopic experiments were performed by a collaborator and the
experimental details followed were as follows.

Spectroscopic T 1 and T2 1H relaxation

measurements of the PLGA composites dispersed in agarose gel were conducted using an
inversion recovery sequence with eight inversion times (TI) and repetition times (TR) at least
five times the expected T1 value. For the T2 measurements, a multi-spin-echo CPMG sequence
was employed with several echo times (TE) and TR values at least five times the expected T 1.
The relaxation times were computed from least-squares fitting of the exponentially varying
signals using analysis routines available at the MR system. Relaxivities were extracted from
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graphs of relaxation rates (1/T1 and 1/T2) versus concentration. The concentration range used for
the relaxivity measurements was in the range 0.0419-0.6700 mM.
6.6.2.MRI results

Figure 6-20: Relaxivity plot for first MRI measurements
In Figure 6-20, the relaxation rates R1=1/T1 and R2=1/T2 are shown as a function of
concentration of the PLGA composites. The relaxivities R 1 and R2, representing the slopes of
these curves, are 0.1 s-1 mM-1 and 58.7 s-1 mM-1 respectively. Iron oxide nanoparticles are known
to be T2 enhancement agent as they have high magnetic susceptibilities and generate high
magnetic field gradients near their surfaces. These gradients create local magnetic field
inhomogeneities that cause rapid dephasing of nearby proton spins, thus increasing proton
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transverse relaxivities (R2) which is evident from the relaxivity plot. A negligible reduction in
the transverse relaxivity (R2) is observed due to the polymeric coating on the nanoparticles.

Figure 6-21: MRI T2-weighted image of the PLGA composites sample in agarose with
varying concentration of the magnetite (iron oxide) nanoparticles.

As discussed earlier the iron oxide (magnetite) nanoparticles are effective in reducing the
T2 relaxation time, thereby inducing a signal darkening on the T 2-weighted MRI images. As
seen in Figure 6-21 as the concentration of the iron oxide nanoparticles increases the image
contrast the respective micro-centrifuge tubes increases. This phenomenon is caused by the
significant enhancement of transverse proton relaxation in the vicinity of areas containing
magnetic iron oxide, thus leading to quick fading of MR signals.

6.7. Conclusion
In conclusion, the chloroform based ferrofluid containing monodisperse magnetite
nanoparticles were produced using thermolysis technique. The magnetite nanoparticles of the
ferrofluid were mono-dispersed with an average diameter of 10± 5 nm and were highly magnetic
with a saturation magnetization of 105 emu/g. The ferrofluid was found to be stable over six
months. The PLGA composites were synthesized using the ferrofluid and Rhodamine B dye by
modified oil-in-water emulsion evaporation technique.

The PLGA composites were further

140

functionalized with folic acid to achieve targeted delivery.

The release of the dye from the

PLGA composite when place in a Rf induction coil was determined by fluorescence
spectroscopy and an increase in the fluorescent intensity was observed with increase in the Rf
induction heating time.

A pulsed Rf treatment of the PLGA composites was also carried out

which shows a corresponding increase in the rate of dye release when the composites are heated
(RF pulse ON) and rate decrease (RF pulse OFF). The dye is released from the PLGA
composites due to the swelling of the polymer and this is confirmed by dynamic light scattering
measurements. Magnetic resonance imaging was also performed using the PLGA composites
which showed enhancement in the T2-weighted image contrast and thus negligible reduction in
the contrast capabilities of the iron oxide particles (R2 = 58.7 s-1 mM-1). The PLGA composites
containing the dye and the iron oxide nanoparticles thus show a potential for being a dual modal
imaging and therapeutic delivery system with reduced drug related toxicity and better drug
activity.
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Chapter 7. Conclusions
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The goal of this dissertation was to design a dual modal controlled release drug delivery
system with cellular targeting capabilities. As discussed in this dissertation the design of the
drug delivery carrier consisted of magnetic nanoparticles as a core with a biocompatible polymer
coating.

The incorporating of magnetic iron/iron oxide nanoparticles into the polymeric

composites was to achieve local heating of the composites through magnetic hyperthermia
principles. These polymeric composites are expected to be superior to conventional routes of
drug administration because the use of nanocomposites would improve the lifetime of the drug in
the circulation, increase the accumulation of the drug at the tumor site through specific site
reorganization mechanism, increase the time that the tumor would be exposed to the drug, and
minimize the amount of drug able to enter healthy tissue as a result of the entrapment of the drug
within a polymeric matrix. A summary of some of the main conclusions in this dissertation work
is presented as below:
1. The first step in the design of the drug delivery was to achieve a complete polymeric
coating on the magnetic iron oxide nanoparticles. Magnetic iron oxide nanoparticles
were synthesized by one-pot polyol technique. This process enabled the liquid polyol to
act not only as a solvent, but also as a mild reducing agent and a surfactant for the
stabilization of the nanoparticles. The iron oxide nanoparticles synthesized were then
coated with a copolymer of styrene- poly (styrene-co-vinylbenzylchloride-codivinylbenzene) (PSVBDVB) which has better mechanical properties compared to
polystyrene. Also, monomer vinylbenzylchloride used has chlorine on its para position
that doesn’t interfere in the polymerization process and provides a site for further
functionalization of the polymer through nucleophilic substitution reactions. Complete
encapsulation of the iron oxide nanoparticles with PSVBDVB copolymer was achieved
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through precipitation polymerization process and was evident from the SEM images of
the copolymer composites. The results indicated that the iron oxide nanoparticles are not
only incorporated into the copolymer matrix but also act as nucleation sites for the
polymerization process to begin. The polymerization process was found to have no effect
on the magnetization of the nanoparticles. But the nanoparticles had several effects on the
resultant polymeric composite size and morphology. As the loading of the nanoparticles
was increase during the polymerization process, a decrease in the composite diameter
was observed. Also an increase in the polydispersity, and decrease in the uniformity of
the polymeric composition was detected. These effects of nanoparticle loading reported
give insight into parameters that may need to be adjusted in order to obtain monodispersed polymeric composition with better mechanical properties.
2. In the second phase of the design of drug delivery system, the PSVBDVB polymer was
replaced by a biocompatible and biodegradable polymer- Poly (lactide-co-glycolide)
(PLGA). It has been approved by FDA for human applications. The PLGA composites
containing the Fe@FeOx core shell nanoparticles and the drug analog [Ru(bpy) dye] was
prepared by oil-in water emulsion solvent evaporation technique. The PLGA composites
prepared were spherical but had a wider size distribution in the range of 500 nm to 2.5
μm. The local heating of the PLGA composites was also achieved by irradiating the
Fe@FeOx nanoparticles with 2.45 GHz microwave radiations. The Ru(bpy) dye can be
quenched by iron oxide nanoparticles. A decrease in the fluorescent intensity of the
PLGA composites was observed when the composites were heated by microwaves or
external heat source. This decrease in intensity observed was speculated to be due to the
quenching of the released dye by the iron nanoparticles. The release of the Ru(bpy) dye
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from the PLGA composites after microwave irradiation was successfully achieved. Also
higher Ru(bpy) dye release from the composites by locally heating the sample with 2.45
GHz microwave pulse compared to externally heating the composite sample was
demonstrated.
3. The final step is the design of controlled release drug delivery system with dual modal
imaging and therapeutic capabilities. For an efficient drug delivery carrier the carrier size
plays and important role, so the Fe@FeOx nanoparticles previously used were replaced
by a chloroform based ferrofluid. The ferrofluid was synthesized by novel thermolysis
technique using sodium oleate as the surfactant. The synthesized ferrofluid consisted of
mono-dispersed 10±5 nm in diameter. The nanoparticles were highly magnetic with
saturation magnetization reaching 105 emu/g and 5 Oe corecivity. The ferrofluid and the
drug analog-Rhodamine B dye were encapsulated into the PLGA polymer by modified
oil-in-water emulsion technique and were confirmed by SEM. For achieving specific
targeting capabilities the PLGA composites were functionalized with folic acid. The folic
acid attachment to the PLGA was confirmed by IR and UV-Vis spectroscopy. The FAPLGA composites were synthesized by the same modified oil-in-water emulsion
technique. The release of the dye from the PLGA composites when placed in the Rf
induction coil was determined by fluorescence spectroscopy and a linear increase in the
fluorescent intensity was observed with time. The increase in the fluorescent intensity is
observed indicating that the dye is released from the PLGA composites when locally
heated. Also, the controlled release of the dye from the composites was achieved by a
pulsed Rf treatment.

Increase in the intensity is observed when the composites are

heated with the Rf pulse ON and rate decreases when the Rf pulse is switched OFF. This
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result confirms successful design of a controlled release therapeutic delivery system. The
dye is released from the PLGA composites due to the swelling of the polymer and this is
confirmed by dynamic light scattering measurements. Magnetic resonance imaging was
also performed using the PLGA composites which showed enhancement in the T 2weighted image contrast and thus negligible reduction in the contrast capabilities of the
iron oxide particles (R2 = 58.7 s-1 mM-1).

The PLGA composites containing the

Rhodamine B dye and the iron oxide nanoparticles thus constitute a controlled release
drug delivery system with dual modal imaging and therapeutic capabilities.
The present research contributed to the understanding of key parameters in the
preparation of polymeric composites for therapeutic and imaging purposes. This work
has added much to the understanding of the drug delivery system, and part of the ongoing
work includes on achieving a stable water dispersion of the FA functionalized PLGA
composites. Also a detailed cytotoxicity and intracellular uptake study of the composites
needs to be done for further understanding the biological aspects needs to be concentrated
for achieving an enhanced drug delivery system capable of replacing the conventional
routes of drug administration.

7.1. Future work
7.1.1. Drug delivery application
The future step in the designing of the PLGA based drug delivery system is the
incorporation of the anticancer drugs such as doxorubicin, paclitaxel, or platinum based drugs
which are known to cause general toxicity. These drugs can be incorporated in the PLGA
composites in the same manner by oil-in-water emulsification solvent evaporation technique in
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which the drug analog- fluorescent dyes were incorporated in the present research. 203 For
monitoring the release of the anticancer drugs from the PLGA composites, fluorescent tagged
anticancer drugs can be used. The fluorescent tagging of the anticancer drugs makes it easy to
monitor its release through fluorescent spectroscopy that has been very well established in this
dissertation work.

Also the drug release can also be determined by HPLC, and UV-Vis

spectroscopy depending on the type of anticancer drug used. For example if doxorubicin is used
as the active therapeutic agent, the encapsulation doxorubicin in PLGA composites can be
determined by UV-Vis spectroscopy. Doxorubicin shows a absorbance maxima at 480nm that
can be utilized to determine the drug concentration using a calibration curve method.204,205
It is also important to study the cytotoxicity of the prepared drug carrier. Cytotoxicity
experiments need to be conducted on the prepared PLGA composites. The initial step would be
to determine in-vitro cytotoxicity of the PLGA controls- the PLGA composites by itself and the
PLGA composites containing the magnetic iron/iron oxide nanoparticles and finally the drug
loaded magnetic PLGA composites. The next step has to be the in-vitro study of the heating
effects of the composites on cell lines. It is necessary to confirm that the heat generated by the
magnetic nanoparticles is within the defined hyperthermia range (42-46º C). The increase in the
temperature of the sample when placed in the Rf induction coil can be measured by utilizing a
fiber optic based thermometer. And the final step is to study the specific binding of the PLGA
composites to the folate receptor on the cancerous cells.
7.1.2. Magnetic cell separation
Magnetic cell separation is a technique of cell sorting by incubating with magnetic
nanoparticles coated with appropriate targeting ligands such as antibodies or proteins. 156,206
These surface coated magnetic nanoparticles bind to the call surface and can be magnetically
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separated from the mixture and purified.

The magnetic cell separation technique does not

require a separating column.207 It can be carried out in the sample tubes in liquid phase. The
iron oxide nanoparticles loaded poly (styrene-co- vinylbenzylchloride-co-divinylbenzene)
(PSVBDVB) composites prepared can be further functionalized with an appropriate targeting
ligand and can be used for magnetic cell separation. The PSVBDVB composites can be
functionalized with reactive dyes, e. g., Cibachrom Blue F3GA, or Procion Red for purification
of purification of lysozyme, albumin, and lactate dehydrogenase. 207,208

The PSVBDVB

composites can also be functionalized with streptavidin for isolation of biotinylated
proteins.209,210
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